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ABSTRACT 
 
Chronic pain affects approximately one in five adults, resulting in a greatly reduced 
quality of life and a higher risk of developing co-morbidities such as depression. 
Among different forms of persistent pain, neuropathic pain represents a difficult task 
for therapy and basic research. Despite recent rapid development of neuroscience and 
modern techniques related to drug discovery, effective drugs based on clear basic 
mechanisms are still lacking. A deepened understanding of the molecular 
mechanisms underlying chronic pain states is needed for the discovery of new and 
improved therapies. 
Neuropathic pain is triggered by lesions to the somatosensory nervous system that 
alter its structure and function so that pain occurs spontaneously and responses to 
noxious and innocuous stimuli are pathologically amplified. The pain is an 
expression of maladaptive plasticity within the nociceptive system, a series of 
changes that constitute a neural disease state. Multiple alterations distributed widely 
across the nervous system contribute to complex pain phenotypes. These alterations 
include ectopic generation of action potentials, facilitation and disinhibition of 
synaptic transmission, loss of synaptic connectivity and formation of new synaptic 
circuits, and neuroimmune interactions. 
The endogenous Opioid System is probably the most important system involved in 
control of nociceptive transmission. Both the dynorphin and nociceptin systems have 
suggested as key mediators of some aspects of chronic/neuropathic pain. Beside 
these system, an important role for the brain derived neurotrophic factor (BDNF) has  
been recently suggested since its involvement in the peripheral and central 
sensitization phenomena is known.  
Based on these evidences, here we studied neuroplastic alterations occurring in 
chronic pain conditions, in mice subjected to the right chronic constriction injury 
(CCI). First we investigated the gene expression alterations of the both BDNF and 
Opioid System in spinal cord (SC) and dorsal root ganglia (DRGs) of injured mice at 
different intervals of time. A transient up-regulation of pBDNF and pDYN was 
observed in SC, while increasing up-regulation of ppN/OFQ was found in the DRGs 
of injured mice compred to controle ones. 
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Based on the growing importance attributed to the cerebral neuroplastic alterations 
we also investigated in the same experimental conditions gene expression changes of 
these systems in different brain areas fourteen days after surgery. We found gene 
expression alterations in several areas of CCI mice. We observed up-regulation of 
pBDNF mRNA levels in the amygdala and in the prefrontal and anterior cingulate 
cortices, while a down-regulation of its gene expression in the thalamus. Moreover, 
an up-regulation of pDYN gene expression in the prefrontal and anterior cingulate 
cortices, and a dow-regulation of its mRNA in the brainstem was determined. 
Concerning nociceptin system, we found ppN/OFQ down-regulation in the 
brainstem, hippocampus, amygdala, nucleus accumbens and caudate putamen, and a 
down-regulation of NOP receptor in the brainstem and caudate putamen. In the same 
brain regions we also determined bioactive nociceptin peptide levels, and elevated 
N/OFQ levels were observed in the amygdale of the lesioned mice. 
Recently, an increasing interest has been given to the elucidation of epigenetic 
mechanisms regulating gene expression changes in different pathological conditions, 
including pain states. Hence, we studied alterations of histone modification in the 
BDNF and DYN gene promoters, in the SC of CCI animals seven days after surgery. 
In particolar, our study revealed a significant decrease of H3K27me3 and H3K9me2, 
repressive marks, and of H3K4me3, activating marks, in the pDYN gene promoter 
region. No changes of histone modifications were observed in the pBDNF gene 
promoter region. In parallel, we also investigated BDNF involvement in neuropathic 
pain through the analysis of the behavioral signs of hyperalgesia and allodynia in a 
strain of mice partially lacking for BDNF, subjected to CCI. A similar development 
of hyperalgesia was observed in ICR/CD-1 and BDNF +/+ (wild type) mice. In 
contrast, a later onset of hyperalgesia was observed in BDNF +/- mice (BDNF 
lacking mice). In addition, BDNF +/- animals exhibited significantly lower signs of 
allodynia than BDNF +/+, in both the cold plate and the acetone tests. 
In the last part of the present study, in order to provide a unique approach to explore 
receptor localization and function in vivo of the N/OFQ-NOPr system, I performed a 
preliminary characterization and validation of an innovative knock-in mouse strain 
NOP-EGFP mice where enhanced Green Fluorescent Protein is attached on the C-
terminal of the NOP receptor. We observed that N/OFQ somministration was able to 
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induce NOP receptor internalization in primary neurons. Analysis on brain slices 
showed that the receptors signalappear to be located in brain regions that have been 
previously demonstrated to contain NOP receptor mRNA and NOP receptor binding 
sites.  This model can be useful for a better characterization of pathophysiological 
role of this system in neuropathic pain. The characterization of the NOP-EGFP mice 
could provide a unique technology useful to answer different questions concerning 
the involvement of N/OFQ-NOPr system in chronic pain condition. 
Overall, our results could be important to partially fill the lack of knowledge of 
which and how neuropeptidergic systems are involved in neuroplastic mechanism 
occurring in neuropathic pain that lead to establish the chronic condition and suggest 
the possibility of using drugs acting on these systems for the treatment of this 
invalidating disease. 
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1.  INTRODUCTION 
 
1.1   Neurobiological bases and types of pain 
 
According to the definition of IASP (International Association for the Study 
of Pain - 1986) and according to the association of O.M.S, "Pain is an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, 
or described in terms of such damage." 
 
The pain  consists of several components: the  physiological-discriminative, the 
emotional-affective and the cognitive-evaluative. Although the emotional and 
cognitive mechanisms influence the pain perception, the physiological-discriminative 
component is the most important especially  for the pharmacological  therapy. 
The nociceptive stimuli are collected in the periphery from specialized free synaptic 
terminals, the  nociceptors. The nociceptors represent the distal part of the nerve 
fibers that are classified according to their velocity of conduction and the type of 
stimulus that activates them. There are two types of fiber: Aδ fibers, fast-conducting 
(6-30 m/s), myelinated, activated by mechanical and thermal stimuli and C fibers, 
unmyelinated, slow-conducting (<2m / s), whose free terminals are represented by 
polymodal nociceptors. These fibers have the neuronal soma in the dorsal root 
ganglia (DRG) and  represent the first-order neurons; their anatomical structure (T-
cells) allows the impulse transmission to a second-order neuron located in the dorsal 
horn of the spinal cord. The afferent fibers of these neurons intersect and run along 
the entire spinal cord ascending through the contralateral portion of the medulla; 
these fibers convey information to specific thalamus nuclei where they synapse with 
the third order neurons which project to cortical areas such as somatosensory, 
anterior cingulate and insular cortices. This spino-thalamic tract is defined as the 
ascending pathway of pain control (Fig. 1). 
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 Figure 1.  Schematic representation of the ascending path of pain impulses transmission. 
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The functional activity  of the ascending pathways above described is 
modulated by the descending control system (Fig. 2). This system  is influenced by  
higher brain structures (such as thalamus, amygdala and anterior cingulate cortex) 
and originates from  the periaqueductal gray (PAG), at the midbrain level, and the 
raphe medullary and pontine nuclei. Monoaminergic fibers from these nuclei (5-HT, 
NA)  run along the dorsal-lateral tracts of the spinal cord and  terminate in the 
laminae of the spinal cord. These fibers control the first-order neuron activity, either 
directly or through the activation of an inhibitory interneuron, and are also able to 
modulate the second order neurons activity through postsynaptic receptors activation 
by reducing the excitability. Overall, the pain control descending patways is able to 
produce a reduction of the peripheral nociceptive input (Carbone E. et al. 2009). 
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Figure 2. Schematic representation of the descending path of pain impulses transmission. 
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Concerning type of pain, there are four main categories of pain more or less 
similar to each other.  
Nociceptive pain is a type of pain which all people have experienced. It is an alarm 
mediated by high-threshold unmyelinated C or thinly myelinated Aδ primary sensory 
neurons that feed into nociceptive pathways of the central nervous system (CNS). 
These nociceptor neurons express specialized transducer ion channel receptors, 
mainly transient recep- tor potential (TRP) channels, tuned to respond to intense 
thermal or mechanical stimuli as well as exogenous and endogenous chemical 
mediators. For nociceptive pain to subserve its protective function, the sensation 
must be so unpleasant that it cannot be ignored. Nociceptive pain occurs in response 
to noxious stimuli and continues only in the maintained presence of noxious stimuli. 
It alerts us to external stimuli, such as pinprick or excessive heat, and internal 
stimuli, such as myocardial ischemia in patients with coronary artery disease. Certain 
diseases may generate recurrent or ongoing noxious stimuli to produce chronic 
nociceptive pain as osteoarthritis. (Costigan M. et al. 2009). 
Inflammatory pain occurs in response to tissue injury and the subsequent 
inflammatory response. Here the imperative shifts from protecting the body against a 
potentially damaging noxious stimulus to addressing the consequences of damage. 
To aid healing and repair of the injured body part, the sensory nervous system 
undergoes a profound change in its responsiveness; normally innocuous stimuli now 
produce pain and responses to noxious stimuli are both exaggerated and prolonged. 
Heightened sensitivity occurs within the inflamed area and in contiguous 
noninflamed areas as a result of plasticity in nociceptors and central nociceptive 
pathways (Costigan M. et al. 2009). 
Dysfunctional pain is caused by a malfunction of the somatosensory apparatus and 
this malfunction can be considered a disease in its own right. Dysfunctional pain 
occurs in situations in which there is no identifiable noxious stimulus nor any 
detectable inflammation or damage to the nervous system. It is unclear in most cases 
what causes the manifestation or persistence of dysfunc- tional pain. This syndrome 
share some features of neuropathic pain (Costigan M. et al. 2009). 
Neuropathic pain is a chronic pain state caused by a lesion or disease affecting the 
somatosensory system alters nociceptive signal processing so that pain is felt in the 
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absence of a stimulus, and responses to innocuous and noxious stimuli are enhanced 
(Costigan M. et al. 2009). It can be divided into central or peripheral neuropathic 
pain based on the anatomical location of the injury or disease: peripheral nervous 
system (PNS, eg. Peripheral nerves, dorsal root ganglia (DRG) and dorsal root) and 
central nervous system (CNS, eg . spinal cord and thalamus). 
 
 
1.2  Neuropathic Pain 
 
Neuropathic pain is caused by pathology involving directly or indirectly the 
nervous system. The pathology can be due to diseases that involve the nervous 
system (e.g., AIDS and diabetes), to dysfunction of the nervous system (e.g., 
following stroke), or to a traumatic injury of the nervous system. The pathology can 
involve the peripheral nervous system, the central nervous system, or both. 
Nerve trauma can occur in the peripheral or the central nervous system. 
Peripheral lesions can be caused by nerve compression, limb amputation, or 
traumatic injuries and commonly result in dysesthesias, paresthesias, or chronic 
neuropathic pain. After limb amputation, painful sensations may be perceived as 
originating in the missing part of the body (Casale R. et al. 2009). Pain of central 
origin may occur following spinal cord or brain trauma due to injury, compression 
(by tumors or cysts), or hemorrhagic or ischemic stroke. Not all central nervous 
system traumas result in central pain, but a necessary condition is damage to the 
spinothalamic tract. Moreover, it appears that spinal cord injury induces pain only if 
the gray matter is damaged. 
Various disease states can lead to the development of neuropathic pain. 
Diabetes can often lead to a painful peripheral neuropathy. Diabetic neuropathy is a 
length-dependent neuropathy because it most commonly affects the extremities and 
progresses from more distal to proximal levels. High intracellular glucose levels can 
lead to pathological changes, such as vasoconstriction endothelial hyperplasia, and 
increased oxidative stress. These changes in turn promote neuronal dysfunction 
through decreased nerve blood flow and consequent neural hypoxia. Chronic alcohol 
abuse may also result in a peripheral neuropathy in the lower extremities due to 
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direct degenerative effects on both myelinated and unmyelinated nerve fibers, 
disruption of axonal transport, and enhancement of glutamate neurotoxicity in 
neurons.  
Painful neuropathies can also develop as a result of viral infections. For 
example, after an acute infection of chicken pox, the neurotropic human herpes virus, 
varicella-zoster, remains dormant in the dorsal sensory or cranial nerve ganglia. A 
localized reoccurrence of the varicella-zoster virus (herpes zoster or shingles) can 
occur particularly when the immunesystem is suppressed, as is common in older 
adults or individuals with other immunosuppressive conditions such as Hodgkin’s 
disease or HIV. This is most likely to occur in the dermatomes that had been most 
severely affected by the primary disease. The acute rash and pain are restricted to the 
area of one or several dermatomes and mos  commonly occur in the chest and trunk. 
After the acute viral infection subsides, approximately one-third of patients develop a 
chronic pain condition known as postherpetic neuralgia (PHN). The pain is described 
as burning, tingling, deep aching, itching, or stabbing. The pain in a subset of PHN 
patients is thought to be due to ‘irritable nociceptors.’ These patients report severe 
mechanical hyperalgesia but have minimal sensory loss in the painful area and their 
responses to thermal stimulation remain normal.  
HIV infection commonly leads to the development of neuropathy either by immune 
system and macrophage-mediated axonal degeneration or by toxic effects of antiviral 
treatment medications on mitochondria. Similar to diabetic neuropathy and 
amyloidosis, HIV-induced neuropathy characteristically progresses by first affecting 
the most distal portions of axons. Activation of proinflammatory mediators such as 
tumor necrosis factor-a (TNF-α), interleukin (IL)-6, and nitric oxide in the dorsal 
root ganglia (DRG) is thought to contribute to the axonal damage and to the 
development of a painful neuropathy frequently characterized by bilateral painful 
paresthesias, dysesthesias, or numbness. Autoimmune diseases such as Guillaine–
Barre´ syndrome and multiple sclerosis (MS) cause demyelination and sensory 
deficits including pain. Approximately 80% of Guillaine–Barre´ and 50% of MS 
patients report pain. The etiology of MS is not well-known, although it is believed 
that the onset of the disease involves pathology of the immune system, particularly 
disruption of myelin proteins. Guillaine–Barre´ syndrome has several subtypes based 
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on the suggested etiology of the disease, namely acute inflammatory demyelinating 
polyradiculoneuropathy, acute motor axonal neuropathy, and acute motor and 
sensory axonal neuropathy. T cell disruption of myelin proteins is indicative of the 
first subtype, whereas antibodies to gangliosides are thought to promote 
demyelination and injury in the other two subtypes.  
At the end chemotherapeutic drugs such as vincristine or paclitaxel promote 
microtubule stabilization, thus inhibiting tumor cell proliferation. However, the 
effectiveness of chemotherapy agents is often limited by severe neurotoxic side 
effects. Many patients undergoing paclitaxel chemotherapy develop peripheral 
neuropathies (Borzan J., Meyer R.A. 2009). 
Once neuropathic pain is generated, the sensory hypersensitivity typically 
persists for prolonged periods, even though the original cause may have long since 
disappeared, as after nerve trauma. The syndrome can nevertheless progress if the 
primary disease, such as diabetes mellitus or nerve compression, continues to 
damage the nervous system. Neuropathic pain is not an inevitable consequence of 
neural lesions, though. On the contrary, the pain associated with acute neural damage 
usually transitions to chronic neuropathic pain in a minority of patients (Costigan M. 
et al. 2009). 
For damage of a relatively small nerve, such as the ilioinguinal nerve during hernia 
repair, the risk of persistent (more than two years) pain is on the order of ~5% 
(Kalliomaki M.L. et al. 2008), whereas sectioning a large nerve, such as the sciatic 
nerve or multiple intercostal nerves during thoracotomy, produces sustained 
neuropathic pain in 30%–60% of patients (Ketz A.K. 2008, Maguire M.F. et al. 
2006). Understanding why one individual develops chronic pain and another with an 
effectively identical lesion is spared is obviously crucial to developing strategies to 
abort such transitions (Costigan M. et al. 2009). 
Epidemiological studies on the prevalence of neuropathic pain indicate a high 
incidence (~5%) (Bouhassira D. et al. 2008). Associated risk factors include gender, 
age, and anatomical site of the injury. Emotional and cognitive factors can also 
influence how patients react to chronic pain, but it is much less certain if these 
factors contribute to the risk of developing pain (Costigan M. et al. 2009). 
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1.2.1  Neuropathic Pain symptoms 
 
Patients typically have paradoxical sensory perceptions with pain as a 
dominating positive symptom combined with lesion-induced reduced sensations. 
These perceptions are usually unique and have not been experienced before by 
patients. This coexistence of signs of hypersensitivity and hyposensitivity is quite 
common in neurological disorders; for example, when parkinsonian tremor develops 
after degeneration of the substantia nigra or when spasticity develops after spinal 
cord injury. However, by contrast with these motor disturbances, pain as a subjective 
sensory symptom is not visible, is diffi cult to measure, and involves not only 
physical aspects, but also psychological and emotional components. The 
characteristic sensory abnormalities are crucial findings to correctly diagnose 
neuropathic pain and to distinguish this from other pain types. 
A lesion to a sensory or mixed peripheral nerve with a cutaneous branch, or 
damage to a central somatosensory pathway, characteristically leads to an area of 
sensory defi cit in the related innervation territory. These negative sensory signs can 
include a defi cit in the perception of mechanical or vibratory stimuli, which 
indicates damage to large diameter afferent fibres or to the dorsal column tract, and a 
loss of noxious and thermal percerption, which indicates damage to small diameter 
afferent fibres or to central pain processing pathways such as the spinothalamic tract. 
Electrophysiological techniques and nerve biopsy samples can be useful to help 
assess the attenuation of neuronal function and to document the extent of neuropathy. 
The important question in the management of patients with chronic pain is, however, 
whether their pain is caused by the neuronal lesion or whether other pain disorders 
dominate the clinical picture and coexist with a neuropathy. To diagnose neuropathic 
pain and distinguish it from nociceptive pain it is helpful to analyse the exact quality 
of somatosensory abnormalities. Patients with neuropathic pain almost always have 
areas of abnormal sensation or hypersensitivity in the affected area, which can be 
adjacent to or combined with skin areas of sensory deficit (tab. 1). These positive 
symptoms are paraesthesias (ie, skin crawling sensation or tingling), spontaneous 
(not stimulus-induced) ongoing pain, and shooting, electric shock-like sensations. 
Many patients with neuropathic pain also have evoked pain (ie, stimulus-induced 
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pain and hypersensitivity). Patients usually report mechanical and thermal 
hypersensitivity. Two types of hypersensitivity can be distinguished. First, allodynia 
is defi ned as pain in response to a nonnociceptive stimulus. In cases of mechanical 
allodynia, even gentle mechanical stimuli such as a slight bending of hairs can evoke 
severe pain. Second, hyperalgesia is defined as an increased pain sensitivity to a 
nociceptive stimulus. Another evoked feature is summation, which is the progressive 
worsening of pain evoked by slow repetitive stimulation with mildly noxious stimuli, 
for example, pin pricks. In terms of clinical practice and research, the term allodynia 
is mainly reserved for pain induced by light moving stimuli (mechanical dynamic 
allodynia), whereas the term hyperalgesia is used for other forms of mechanically 
induced pain (Tab. 1) (Baron R. et al. 2010). 
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Table 1.  Definition and assessment of negative and positive sensory symptoms and signs in 
patients with neuropathic pain (Baron R. et al. 2010). 
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1.2.2  Neuropathic Pain models 
  
Animal models provide pivotal systems for preclinical studies of neuropathic 
pain and serve as an experimental basis for mechanistic investigations and testing 
new therapeutic interventions (Colleoni M., Sacerdote P. 2010). 
The ideal models should result in reproducible sensorydeficits such as 
allodynia, hyperalgesia and spontaneous pain over a sustained period. Different types 
of animal models have been established to meet the diverse etiology and 
consequently the diverse manifestations of the neuropathy (JaggiA.S. et al. 2008). 
Most of animal models of neuropathic pain were generated starting from the 
late 1980, using rat as preferred species. More recently pain models originally 
developed in rats have been transposed for use in mice; a strong motive for the  use 
of mice is the availability of genetically characterized or manipulated inbred strains, 
particularly transgenic mouse lines in which specific proteins or signal transduction 
component have been altered throughout genetic knockout technology. In pain 
studies more than in other animal models of disease, particular care has to be given 
to the strains used, since a strong influence of genetic background on pain sensitivity 
exists (Colleoni M., Sacerdote P. 2010).  
A common pitfall of all rodent models of neuropathic pain is the 
inappropriateness of the outcome measures utilized. In fact they focus on stimulus-
evoked pain and hyperreflexia at a particular moment in time, whereas a high 
proportion of patients with neuropathic pain have ongoing, spontaneous pain and 
sensory loss. The recognition of spontaneous pain in experimental animals is 
particularly difficult. Weight loss, sleep disturbances, reduced movement, 
spontaneous paw lifting, scratching or shaking have all been accepted to reflect 
spontaneous pain (Zimmermann M. 2001).  
The numerous models of neuropathic pain in mice (Tab. 2) can be classified 
five gross categories (Colleoni M., Sacerdote P. 2010): 
- central pain models 
- peripheral nerve injury models 
- models of disease-induced neuropathic pain 
- iatrogenic (drug-induced) neuropathic pain, and inherited neuropathies 
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Table 2 List of different animal models of neuropathic pain (Jaggi A.S. et al. 2008). 
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Central pain models mimic neuropathic pain resulting from CNS pathologies 
and  represent a form of neuropathic pain that is associated with lesions of the brain 
or the spinal cord after a stroke or other traumatic injury (Colleoni M., Sacerdote P. 
2010). Different models have been developed such as:  thalamic syndrome resulting 
from stroke, based on a small hemorrhagic stroke lesion induced by collagenase 
injection in the ventral posterolateral nucleus of the rat thalamus (Wasserman J. et al. 
2009); spinal cord injury and contusive model caused by contusion or weight 
dropping, spinal cord compression, excitatory neurotoxins, photochemically induced 
ischemia, spinal cord hemisection, crushing of spinal cord (Starkey M.S. et al. 2009); 
excitotoxic model based on intraspinal or intrathecally injection of some excitoxins, 
such as quisqualic acid or other excitatory aminoacids (Fairbanks C.A. et al. 200); 
photochemical model  based on intravenous injection of the photosensitising dye 
(Gaviria M. et al 2002). 
Regarding peripheral nerve injury model nerve injury to induce hyperalgesia 
and allodynia in rodents, which are similar to the symptoms of neuropathic pain in 
humans. numerous models have been developed in rodents that generate a mixture of 
intact and injured fibres within a peripheral nerve, usually the sciatic, for ease of 
access and its relatively large size. Neuropathic pain behaviour is thought to be 
attributable to altered properties in the intact rather than the damaged fibres. 
Numerous types of nerve lesions have been employed including transection, 
resection, crush, complete or partial tight ligation, cryoneurolysis, and loose ligation 
with inflammatory materials (Fig. 3) (Colleoni M., Sacerdote P. 2010).  
The type of nerve lesion can clearly influence the character of the ensuing 
neuropathic behaviours (Colburn R.W. et al. 1999).  
Various partial nerve lesions have been developed experimentally to study 
neuropathic pain. Such models include chronic constriction injury of the sciatic nerve 
(CCI) (Bennet G.J, Xie Y.K. 1988); partial sciatic nerve ligation (PSL) (Seltzer Z. et 
al. 1990) and spinal nerve ligation (SNL L5/L6) (Kim S.H., Chung J.M. 1992), which 
represent three of the best-characterized rodent models of peripheral neuropathy (Fig. 
3). These classic models produce similar pain behaviours with some variation in the 
magnitude (Bennet G.J. 1993, Kim S.H. et al. 1997). The model of CCI is one of the 
most commonly used models because it is reliable and easily reproducible, and due 
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to the presence of the constrictive ligatures, it combines nerve compression with 
Wallerian degeneration and an epineurial inflammatory lesion. This model in mice is 
produced by three loose ligatures that are tied around the common sciatic nerve 
exposed at the level of the mid-thigh, proximal to the trifurcation of the nerve. This 
procedure results in intraneural oedema, which strangulates the nerve, effectively 
axotomizing many but not all of the nerve axons. It results in the development of 
hyperalgesia to thermal stimulus and allodynia to mechanical stimuli. In contrast 
with CCI model that consists in the ligation of the total sciatic nerve, partial sciatic 
nerve injury that consists in the tight ligation of only 1/3 to 1/2 of the common sciatic 
diameter. Spinal nerve ligation consists of ligating unilaterally and tightly spinal 
nerves L5 and/or L6 of rodents at a location distal to the dorsal root ganglia and 
results in allodynia and hyperalgesia that develop quickly after ligation and last for at 
least 4 months (Colleoni M., Sacerdote P. 2010). 
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Figure 3 Representation of different peripheral nerve injury models (1) spinal nerve ligation 
by tightly ligating L5 and L6 spinal nerves; (2) chronic constriction injury by placing four 
loose ligatures around the sciatic nerve; (3) ligation of common peroneal nerve; (4) axotomy 
model by sciatic nerve transection; (5) partial sciatic nerve ligation by tight ligation of one-
third to half of sciatic nerve; (6) tibial and sural nerve transection model by transaction of 
tibial and sural nerve; (7) spared nerve injury model by transaction of peroneal and tibial 
nerve (Jaggi A.S. et al. 2008). 
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Regarding disease-induced neuropathic pain models trying to induce the 
disease that will thereafter cause the neuropathic damage, such as painful peripheral 
diabetic neuropathy, post-herpetic neuralgia, cancer-associated neuropathic pain, 
multiple sclerosis neuropathic pain, complex regional pain syndrome type I, HIV 
(and antiretroviral)-induced painful neuropathy. Iatrogenic (drug-induced) 
neuropathic pain models are obtained through animals Chemotherapy treatment. 
Finally, in recent years have been created inherited-induced neuropathies models due 
to the use of molecular clones of many membrane proteins localized in the axons 
myelinated junctions and glia (Colleoni M., Sacerdote P. 2010). 
 
 
1.2.3  Mechanisms of Neuropathic Pain 
 
Neuropathic pain is associated with pathological changes at many sites along 
the neural axis. For the spinal nerve ligation model of neuropathic pain, numerous 
abnormalities that may account for neuropathic pain have been identified in both the 
peripheral and the central nervous system (Borzan J., Meyer R.A. 2009). 
Spontaneous neural activity and ectopic sensitivity to mechanical stimuli develops at 
the site of nerve injury. The expression of different molecules in the dorsal root 
ganglion of the injured nerve is up- or downregulated, reflecting the loss of trophic 
support from the periphery. Spontaneous neural activity develops in the DRGs. The 
distal part of the injured nerve undergoes Wallerian degeneration, exposing the 
surviving nerve fibers from uninjured portions of the nerve to a milieu of cytokines 
and growth factors. Partial denervation of the peripheral tissues leads to an excess of 
trophic factors from the partly denervated tissue that can lead to sensitization of 
primary afferent nociceptors. The expression of different molecules in the dorsal root 
ganglion of the uninjured nerve is up- or downregulated, reflecting the enhanced 
trophic support from the periphery. Sensitization of the postsynaptic dorsal horn cell 
develops, leading to an augmentation of the response to cutaneous stimuli. Activated 
microglial cells contribute to the development of this dorsal horn sensitization. 
Changes in descending modulation of dorsal horn neurons also may contribute to the 
enhanced responsiveness of dorsal horn neurons (Campbell J.N., Meyer R.A. 2006). 
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1.2.3.1   Peripheral Nervous System and Ectopic activity 
 
The importance of the peripheral nervous system in neuropathic pain is 
supported by the observation that peripherally acting drugs alter neuropathic pain 
behavior. For example, the cannabinoid receptor 2 (CB2) is selectively expressed in 
the peripheral nervous system, and selective CB2 agonists were effective in reversing 
mechanical and heat hyperalgesia in an animal model of neuropathic pain. In 
addition, peripherally acting opiates have been shown to ameliorate neuropathic pain 
behavior (Borzan J., Meyer R.A. 2009). 
An important feature of neuropathic pain is pain in the absence of an 
identifiable stimulus. Spontaneous pain arises as a result of ectopic action potential 
generation within the nociceptive pathways and does not originate in peripheral 
terminals in response to a stimulus. Theoretically, ectopic activity could be generated 
at any anatomical level proximal to those brain regions that mediate the sensory 
experience. Compelling evidence for peripheral neuropathic pain, however, points to 
substantial ectopic activity arising in primary sensory neurons. After peripheral nerve 
damage, spontaneous activity is generated at multiple sites, including in the neuroma 
(the site of injury with aborted axon growth), in the cell body of injured dorsal root 
ganglia (DRG) neurons, and in neighboring intact afferents. Spontaneous pain may 
arise both from ectopic activity in nociceptors and from low-threshold large 
myelinated afferents  due to central sensitization and altered connectivity in the 
spinal cord. After spinal cord injury, spontaneous pain may result from increases in 
the intrinsic excitability of second-order neurons (Costigan M. et al. 2009). Under 
physiological conditions, activation of unmyelinated (C-fibre) and thinly myelinated 
(Aδ-fi bre) nociceptive afferent fibres indicates potential tissue damage, which is 
reflected in the high thresholds of nociceptors for mechanical, thermal, and chemical 
stimuli. These conditions change dramatically in neuropathic pain states. After a 
peripheral nerve lesion, spontaneous activity is evident in both injured and 
neighbouring uninjured nociceptive afferents (Baron R. et al. 2010) (Fig. 4). 
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Figure 4  Stimulus-response relations and generation of ectopic impulses (Costigan M. et al. 
2009). 
 
 
 
 
Voltage-gated sodium channels contribute largely to the generation of ectopic 
activity as indicated by the robust inhibitory effects of local anesthetics, which are 
nonselective sodium channel blockers (Sheets P.L. et al. 2008). Increasing levels of 
mRNA for voltage-gated sodium channels seem to correlate with ectopic activity, 
and increased expression of sodium channels in lesioned and intact fibres might 
lower action potential threshold until ectopic activity takes place (Baron R et al. 
2010). DRG neurons express several sodium channels however, which of these 
channels is responsible for the abnormal generation of action potentials is not 
entirely clear (Costigan M. et al. 2009). 
Further evidence for the crucial role of voltage-gated sodium channels in chronic 
pain states comes from patients with erythromelalgia and paroxysmal extreme pain 
disorder who have severe ongoing pain at different sites of the body. These 
hereditary disorders are caused by gain-of-function mutations in the SCN9A gene 
that encodes α subunit of the Nav1.7 voltage-gated sodium channel (Hains B.C. et al. 
2007). This channel is expressed predominantly in the small-diameter primary 
afferents and is believed to participate in the action potential initiation at the 
peripheral nerve terminals. 
Whereas the TTX-resistant, sensory neuronspecific channels, Nav1.8 and Nav1.9, 
are reportedly downregulated in injured afferents, Nav1.8 is upregulated in the 
uninjured neighboring fibers (Borzan J., Meyer R.A. 2009). 
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In addition to voltage-gated sodium channels, several other ion channels probably 
undergo alterations after a nerve lesion, such as voltage-gated potassium channels, 
calcium channel and hyperpolarization-activated cyclic nucleotide-modulated 
channel, which might also contribute to changes in membrane excitability of 
nociceptive nerves.  
The hyperpolarization-activated cyclic nucleotide-modulated channel (HCN), which 
contributes to the pacemaker current l(h), also generates ectopic activity in DRG 
neurons after nerve injury (Luo L. et al. 2007). Opening the neuronal voltage-gated 
potassium channel subfamily Q (KCNQ), which is a mediator of the M current, 
selectively reduces activity in axotomized but not uninjured axons (Roza C., Lopez-
Garcia J.A. 2008) and in human C-fiber axons (Lang P.M. et al. 2008), suggesting 
that this channel may be involved in regulating ectopic activity. 
Mice with a deletion of Cav2.2 (the N-type calcium channel) show reduced 
neuropathic pain-like behavior (Saegusa et al. 2001). Intrathecal delivery of ω-
conopeptide MVIIA, which blocks Cav2.2 in a non-use-dependent fashion, decreases 
neuropathic pain in preclinical models and patients, presumably by reducing 
transmitter release from nociceptors (McGivern J.C. 2006). The calcium channel 
auxiliary α2δ1 subunit helps stabilize the poreforming α subunit of these channels in 
the membrane. Gabapentin and pregabalin, among the first-line treatments for 
neuropathic pain (Dworkin R.H. et al. 2007), bind to the α2δ1 protein, interfere with 
the interaction between the auxiliary subunit and the α subunit, and impair membrane 
insertion of the channel (Hendrich J. et al. 2008). Both Cav2.2 and α2δ1 subunits are 
upregulated in DRG neurons following nerve injury (McGivern J.C. 2006), which 
suggests that an N-type calcium channel complex may play a dominant role in 
pathological nociceptive signal transmission from the periphery (Costigan M. et al. 
2009).  
Moreover, nerve injury also induces upregulation of various receptor proteins such as 
the transient receptor potential V1 (TRPV1). TRPV1 is located on subtypes of 
peripheral nocicepive endings and is physiologically activated by noxious heat at 
about 41°C (Caterina M.J. et al. 2001).  After a nerve lesion, TRPV1 is 
downregulated on injured nerve fibres but upregulated on uninjured C-fibres (Ma W. 
et al. 2005). This novel expression of TRPV1 and additional sensitisation to heat by 
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intracellular signal transduction might lead to spontaneous nerve activity induced by 
normal body temperature, if the threshold of TRPV1 is reduced to below 38°C (Bigss 
J.E. et al. 2008). Clinically, patients with such underlying pain mechanisms can also 
be characterised by the presence of heat hyperalgesia in addition to ongoing burning 
pain. Similarly, ongoing ectopic discharges of nociceptive afferent fibres have been 
recently identifyed in a patient with painful neuropathy in combination with cold 
allodynia. Abnormal responses to cold and topical application of menthol indicated 
that a nerve lesion triggered abnormal function or expression of TRPM8, a cold-
sensitive receptor of the TRP family (Serra J. et al. 2009). 
 
 
 
1.2.3.2   Low-Threshold Aβ Fiber-Mediated Pain  
 
Neuropathic pain involves a profound switch in sensitivity such that low-
intensity input can generate pain, a disruption of the normal pattern of pain 
specificity (Perl E.R. 2007). The hypersensitivity occurs largely in the absence of 
peripheral sensitization; includes areas outside of injured nerve territories; is 
typically associated with a loss of C-fiber peripheral terminals, and sensitivity 
(Devigili G. et al. 2008); and disappears when conduction in large myelinated fibers 
is blocked (Campbell J.N. et al. 1988). Furthermore, ablation of the vast majority of 
nociceptor neurons does not alter the development and manifestation of neuropathic 
pain (Abrahamsen B, et al. 2008), whereas selective pharmacological blockade of 
large neurofilament-200-positive Aβ fibers abolishes dynamic tactile allodynia in 
nerve injury models (Yamamoto W. et al. 2008) (Fig. 5). The obvious conclusion 
from these data is that low-threshold Aβ fibers, which normally signal innocuous 
sensations, begin after neural lesions to produce pain (Khan G.M. et al. 2002; Witting 
N. et al. 2006). In keeping with this finding, loss of the PKCγ interneurons in the 
ventral part of the superficial dorsal horn (lamina III) that are driven only by Aβ fiber 
innocuous input (Neumann S. et al. 2008) leads to reduced neuropathic but preserved 
nociceptive pain (Malmberg A.B. et al. 1997). Furthermore, after nerve injury 
polysynaptic and monosynaptic Aβ fiber input to neurons increases in the most 
superficial laminae of the dorsal horn (Okamoto M. et al. 2001), an area that 
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normally only receives input from Aδ and C fibers (Lu Y., Perl E.R. 2005). Although 
noxious stimuli activate ERK MAP kinase in superficial dorsal horn neurons in 
noninjured animals (Ji R.R. et al. 1999), after peripheral nerve injury Aβ fiber 
stimulation acquires this capacity (Matsumoto M.et al. 2008). Tactile stimulation also 
begins to induce c-Fos in these nociceptive neurons (Bester H. et al. 2000). These 
structural changes may be an anatomical substrate for the entry of low-threshold Aβ 
fiber input into nociceptive pathways after nerve injury. Somehow, as a consequence 
of peripheral nerve injury, low-threshold input from large myelinated fibers is 
transferred from nonnociceptive to nociceptive circuits in the spinal cord (Costigan 
M et al. 2009). This means that normally innocuous tactile stimuli such as light 
brushing or pricking the skin become painful. Similar mechanisms might take place 
not only within the spinal cord, but also at supraspinal levels, as has been reported in 
patients with central pain (Baron R. et al. 2010). 
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Figure 5 Pathophysiological mechanisms of neuropathic pain  
Primary aff erent pathways and their connections in the spinal cord dorsal horn. Note that nociceptive 
C-fi bres (red) terminate at spinothalamic projection neurons in upper laminae (yellow neuron). Non-
nociceptive myelinated A-fi bres project to deeper laminae. The second-order projection neuron is a 
WDR type—it receives direct synaptic input from nociceptive terminals and also multisynaptic input 
from myelinated A-fi bres (non noxions information, blue neuron system). Interaction with microglia 
(grey cell) facilitates synaptic transmission. GABAergic interneurons (green neuron) normally exert 
inhibitory synaptic input on the WDR neuron. Furthermore, descending modulatory systems synapse 
at the WDR neuron (only the inhibitory projection, green descending terminal) (Baron R. et al. 2010). 
 
 
 
 
 
 
  
 
24 
 
1.2.3.3   Peripheral sensitization  
 
Following many types of tissue injury, including nerve injury, primary 
afferents develop lower activation threshold, become more responsive to natural 
stimuli, and develop larger receptive fields. In other words, they become sensitized. 
A change occurs in the transduction mechanisms that convert external stimuli (heat, 
touch, etc.) to electrical signals of neurons. After injury, proteins and ion channels in 
the primary afferents can undergo structural changes (e.g., phosphorylation) or 
primary afferents can develop altered gene expression that signals the production of 
new molecules. Consequently, previously nonnoxious stimuli may now be sufficient 
to activate a given channel or receptor, they may remain active for a longer period of 
time, or new channels may become activated by different factors within the injury 
site. These changes are responsible for peripheral sensitization. It is well known that 
cyclo-oxygenase enzymes play a role in inflammatory pain conditions by converting 
arachidonic acid into proinflammatory factors such as prostaglandin E2 (PGE2). 
Prostaglandins have also been shown to contribute to peripheral sensitiza- tion in 
neuropathic pain by shifting the activation threshold of tetrodotoxin-resistant sodium 
channels (TTX-R Naþ) Nav1.8 and Nav1.9. PGE2 binds to G-protein-coupled 
receptors and increases cyclic AMP, which can sensitize TTX-R Naþ channels by 
activating protein kinases A and C.  
Following peripheral nerve lesion, peripheral sensitization occurs in the 
uninjured fibers innervating the same territory. Sensitization of uninjured fibers 
occurs partly because Wallerian degeneration of the injured nerve results in a release 
of a number of proinflammatory factors, including cytokines and growth factors, that 
can alter the activation threshold of the surviving neurons. These changes drive to 
sensitivity of uninjured afferents to chemical (TNF-α), mechanical, and heat stimuli 
following peripheral nerve injury (Borzan J., Meyer R.A. 2009)(Fig. 6).  
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Figure 6 Peripheral changes at primary aff erent neurons after a partial nerve lesion, leading 
to peripheral sensitisation.  
Some axons are damaged and degenerate (axons 1 and 3) and some are still intact and connected to 
the peripheral end organ (skin; axons 2 and 4). Expression of sodium channels is increased on 
damaged neurons (axon 3), triggered as a consequence of the lesion. Furthermore, products such as 
nerve growth factor, associated with Wallerian degeneration and released in the vicinity of spared fi 
bres (arrow), trigger expression of channels and receptors (eg, sodium channels, TRPV1 receptors, 
adrenoreceptors) on uninjured fi bres (Baron R. et al. 2010). 
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1.2.3.4   Central nervous system and central sensitization 
 
Peripherally directed treatments do not always help in alleviating neuropathic 
pain, indicating that changes also occur in the central nervous system. Nerve injury 
can lead to sensitization of central pain-signaling neu- rons as well as changes in the 
properties of the inhibi- tory interneurons and descending inhibition (Borzan J., 
Meyer R.A. 2009). 
Central sensitisation might develop as a consequence of ectopic activity in 
primary nociceptive afferent fibres and structural damage within the CNS itself 
might not be necessarily involved. Ongoing discharges of peripheral afferent fibres 
that release excitatory aminoacids and neuropeptides within the dorsal horn of the 
spinal cord lead to pre- and postsynaptic changes and altered response of these 
central of second neurons (Baron R. et al. 2010). Presynaptic functional changes 
include alterations in the synthesis of transmitters and neuromodulators (Obata K. et 
al. 2003) and in calcium channel density (Hendrich J. et al. 2008). Postsynaptic 
changes involve phosphorylation of N-methyl-D-aspartate (NMDA) subunits and 
AMPA receptor (Ultenius C. et al. 2006) and increased receptor density due to 
trafficking and enhanced synthesis of ion channels and scaffold proteins (Cheng H.T. 
et al. 2008). 
Wind-up is a single synapse phenomenon of enhanced responsiveness of a 
central neuron following continuous low-frequency nociceptor activation from the 
periphery. Central sensitization can result from spatial and temporal summation of 
wind- up. Wind-up is a short-lasting phenomenon (tens of seconds) largely mediated 
by glutamatergic activation of NMDA receptors. Hence, blocking NMDA recep- tors 
abolishes wind-up to various stimuli in healthy individuals and reduces neuropathic 
pain in select con- ditions, such as painful phantom limb and PHN (Borzan J., Meyer 
R.A. 2009).  
Drugs that attenuate central sensitization by acting on calcium chan- nel 
subunits to decrease transmitter release and on NMDA channels to reduce transmitter 
action are effective treatment options in neuropathic pain (Costigan M. et al. 2009) 
even if secondary hyperalgesia (pain in the area surrounding the injury and attributed 
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to central sensiti- zation) is generally not altered by inhibiting NMDA receptors 
(Borzan J., Meyer R.A. 2009). 
Enhanced responsiveness of dorsal horn neurons after central sensitization lasts for 
prolonged periods of time, suggesting additional or alternative mechanisms to the 
wind-up phenomenon. Specifically, the release of substance P from primary afferent 
neu- rons can facilitate depolarization of dorsal horn neurons by directly activating 
NK-1 receptors and by subsequent modulation of NMDA receptor activation (Borzan 
J., Meyer R.A. 2009).  
Although central sensi- tization was first described in the dorsal horn, similar 
synaptic changes occur in structures involved in the emotional aspects of pain such 
as the amygdala, anterior cingulate gyrus, and prefrontal cortex (Pedersen L.H. et al. 
2007), and these may represent a substrate for long-term cognitive and mood changes 
that are learned and retained, for example, conditioned fear and addictive behavior.  
Central sensitization is different from centralization, which hypothesizes that, after 
pe- ripheral nerve injury, changes intrinsic to the CNS develop and maintain pain 
independent of any ongoing peripheral input (Devor M. 2006). These changes 
potentially include increased ex- citability (Balasubramanyan S. et al. 2006), 
structural alterations in synaptic circuitry (Woolf C.J. et al. 1992), degeneration of 
inhibitory in- terneurons (Scholz J. et al. 2005), and alterations in the brain stem 
regulation of nociceptive transmission (Vera-Portocarrero L.P. et al. 2006).  
 
 
1.2.3.5   Disinhibition 
  
Some of the spinal cord interneurons rich in GABA, glycine, or opioid 
peptides have an inhibitory influ- ence on synaptic transmission (Borzan J., Meyer 
R.A. 2009). Pharmacological removal of GABAergic or glycinergic control provokes 
tactile allodynia  and increases synaptic currents from Aβ fibers to nociceptive 
lamina I neurons (Costigan M. et a. 2009). Peripheral nerve injury can lead to 
impaired tonic inhibitory function of these interneurons by reducing the synthesis or 
release of inhibitory neurotransmitters or to apoptosis of these interneurons due to 
glutamate neurotoxicity (Borzan J., Meyer R.A. 2009).  
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Descending pathways that modulate the spinal transmission of nociceptive 
input orig- inate in the anterior cingulate gyrus, amyg- dala, and hypothalamus and 
are relayed to the spinal cord through brain stem nuclei in the periaqueductal gray 
and rostroven- tral medulla. The inhibitory transmitters in these pathways include 
norepinephrine, 5-hydroxytryptamine, and endogenous opioids. After nerve injury, 
this intricate system of inhibitory control shifts. Tonic noradrenergic inhibition that 
acts on α2-adrenoceptors appears to be suspended (Rahman W. et al. 2008), and the 
net effect of descending serotoniner- gic input changes from inhibition to facilitation 
(Bee L.A., Dickenson A.H. 2008, Vera-Portocarrero L.P. et al. 2006). Amine uptake 
inhibitors like tricylic antidepressants or serotonin nore- pinephrine reuptake 
inhibitors (SNRIs) boost endogenous inhibition by increasing the levels of 
norepinephrine (Matsuzawa-Yanagida K. et al. 2008).  
Some studies indicate that endogenous opioids serve an anti- nociceptive role 
following nerve injury. Mice lacking the m opioid receptors show enhanced nerve 
injury-induced behavioral hyperalgesia and wind-up compared to wild-type animals. 
Intrathecal administration of delta opioid ago- nist reversed mechanical and cold 
hyperalgesia following spinal nerve ligation (Borzan J., Meyer R.A. 2009).Following 
nerve injury, primary afferents reduce their expression of µ opioid receptors, and 
dorsal horn neurons are less sensitive to inhibition by µ opioid agonists (Kohno T. et 
al. 2005).  
Furthermore, several different mechanisms contribute to a loss of pre- and 
postsynaptic GABAergic inhibition in the spinal cord. In nociceptive lamina I 
neurons, the transmem- brane gradient for chloride ions changes after nerve injury so 
that activation of GABAA receptors no longer leads to hyperpolarization. Instead, it 
may induce depolarization, provoking paradoxical excitation and spontaneous 
activity (Keller A.F. et al. 2007). BDNF released from active microglia causes this 
disturbance by inducing a downregulation of the potassium chloride cotransporter 
isoform 2 (Coull J.A. et al. 2005) (Fig. 7). 
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Figure 7 A pathway of pain. Microglial neuronal signaling mediated by BDNF disrupts 
inhibition of rat lamina I spinal-cord neurons and maintains neuropathic pain.  
a) Activation of GABAA receptors (GABAAR) normally leads to an influx of anions (principally 
chloride, Cl-), causing hyperpolarization (inhibition), because the potential at which the anion flux 
switches from inward to outward (Eanion) is negative with respect to the resting membrane potential of 
the neuron (Vrest).  
b) Following peripheral nerve injury, activated microglia (with ATP-stimulated P2X4 receptors) 
release BDNF, which acts on the TrkB receptor to modify Eanion, probably by reducing levels of the 
potassium-chloride co-transporter KCC2. As Eanion is now positive with respect to Vrest,  GABAA-
receptor activation leads to an efflux of anions, depolarizing the lamina I neurons. Blockade  of this 
microglial–neuronal signalling pathway alleviates chronic neuropathic pain in the rat model (Torsney 
C., Macdermott A.B. 2005). 
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Independently, inhibition in the superficial dorsal horn of the spinal cord is 
compromised by a loss of GABAergic interneurons (Scholz J. et al. 2005), reducing 
afferent stimulation-evoked GABAergic inhibitory postsynaptic currents (IPSCs) 
(Moore K.A. et al. 2002). Preventing apoptotic cell death fully restores GABAergic 
IPSCs and attenuates mechanical allodynia, hyperalgesia, and cold allodynia after 
nerve injury (Scholz J. et al. 2005). Loss of spinal inhibitory interneurons may 
contribute to the persistence of neuropathic pain, although pain-like behavior after 
sciatic nerve injury in the absence of neuronal cell death has been reported (Polgar 
E. et al. 2005). Despite the apparent role of GABAergic disinhibition in neuropathic 
pain, GABAA receptor modulators such as benzodiazepines or GABAB receptor 
agonists are rarely used to treat neuropathic pain because they have a narrow 
therapeutic window. Specific GABA agonists that bind to the α2 or α3 but not α1 
subunits of spinal GABAA receptors may allow analgesia without sedation or motor 
impairment (Knabl J. et al. 2008).  
 
 
1.2.3.6   Neurodegenerazione 
  
Both primary sensory and dorsal horn neurons die after peripheral nerve 
injury. Primary afferents degenerate after transection of their peripheral axons, with a 
much greater loss of small-diameter neurons, including nociceptors, than large 
myelinated neurons (Okamoto M. et al. 2001, Tandrup T. et al. 2000). A loss of 
~20% of superficial dorsal horn neurons occurs after partial peripheral nerve injury. 
The degeneration of spinal neurons occurs protracted over several weeks and is most 
likely a consequence of sustained ectopic activity of primary sensory afferents and 
glutamate-mediated excitotoxicity (Scholz J. et al. 2005). Magnetic resonance 
imaging (MRI) investigations in patients with chronic neuropathic pain hint that 
neurodegeneration may also occur in the brain. Voxel-based morphometry shows 
decreases in gray matter volume and density in MRIs of the brain of patients with 
chronic back pain, phantom pain, migraine, tension-type headache, and fibromyalgia, 
although with varying degree and regional distribution (May A. 2008). The nature of 
these structural changes remains to be determined, as well as whether 
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neurodegeneration is a cause and if analgesic treatment can prevent the changes. 
These findings raise the possibility that neuropathic pain may have elements that 
resemble neurodegenerative diseases and requires neuroprotective treatment 
strategies (Costigan M. et al. 2009).  
 
 
1.2.3.7  Role of the Sympathetic Nervous System 
  
In some patients, blockade of the sympathetic nervous system leads to pain 
relief. This sympathetically maintained pain (SMP) is thought to depend on the 
peripheral release of norepinephrine from sympathetic efferent fibers that activates 
and sensitizes primary afferents. Animal studies have shown that peripheral nerve 
injury can result in de novo expression of a1 adrenergic receptors in adjacent 
uninjured afferents and sensitization to adrenergic agonists, indicating that the 
coupling site between the sympathetic and pain systems may be in the primary 
afferent fibers. In human studies, intradermal norepinephrine injections caused pain 
in patients with SMP but not in healthy controls. Some patients with complex 
regional pain syndrome have SMP and gain pain relief following sympathetic 
ganglion block or after intravenous administration of phentolamine, an a-adrenergic 
antagonist. The sympathetic nervous system has been implicated in central pain 
mechanisms as well. Neuropathic pain patients with strokeinduced central pain 
frequently complain of exacerbated pain under stress and have areas of abnormal 
blood flow and sweating (Borzan J., Meyer R.A. 2009).  
 
 
1.2.3.8  Influence of the Immune system 
 
In addition to the obvious role of the immune system in inflammatory pain, 
there is accumulating evidence that immune factors are of importance in neuropathic 
pain (Borzan J., Meyer R.A. 2009).  
In the PNS, immune surveillance is performed by macrophages, which 
identify and clear cellular debris and present surface antigens to activate T-
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lymphoctyes. Both macrophages and T-lymphocytes communicate via cytokines and 
chemokines with neurons, Schwann cells, and DRG satellite cells. Macrophage 
activation is a central component of the Wallerian degeneration distal to axonal 
injury, and immune activation in the injured nerve and DRG appears to contribute to 
pain hypersensitivity (Scholz J., Woolf C.J.  2007).  
Damaged or denervated Schwann cells secrete leukemia inhibitory factor 
(LIF) and monocyte chemoattractant protein-1 (MCP-1). Upregulation of LIF 
following injury results in increased release of substance P and other molecules that 
contribute to nociceptor sensitization. MCP-1 is a chemokine cytokine that binds to 
chemokine receptor CCR2 and has been shown to activate monocytes and depolarize 
nocicep- tors following nerve injury either directly or by promoting the release of 
proinflammatory factors from surrounding nonneuronal cells. Cytokine IL-1β 
promotes expression and release of NGF that can lead to sensitization of primary 
afferents. Deletion of IL-1β or overexpression of IL-1βantagonist largely diminished 
the development of neuropathic pain following spinal nerve ligation or axotomy. 
These results complement previous evidence that injection of IL-1β or TNF-α in the 
sciatic nerve causes mechanical and heat hyperalge- sia (Borzan J., Meyer R.A. 
2009). 
Microglia, the macrophages of the CNS, are massively activated in the dorsal 
horn soon after peripheral nerve injury. Microglial activation occurs in a 
topographically organized fashion close to the central terminals of injured afferents 
(Beggs S., Salter M.W. 2007, Scholz J. et al. 2008), and microglial cells release many 
immune modulators that contribute to the induction and maintenance of neuropathic 
pain by altering neuronal function (Saab C.Y. et al. 2008, Suter M.R. et al. 2007) For 
example, painful peripheral neuropathy due to HIV infection may also be caused in 
part by spinal cord microglia activation. Various approaches to inhibit microglial 
activation provide direct support that immune cell activation in the central nervous 
system contributes to neuropathic pain, especially in its development (Borzan J., 
Meyer R.A. 2009). 
Immune cells may influence neuronal activation and sensitization through 
upregulation of purinergic receptors and chemokines, activation of various kinases, 
and release of various cytokines. Microglia express a number of purinergic receptors. 
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Two have been demonstrated as important in neuropathic pain: P2X4 and P2X7; 
these receptor, activated through ATP (Inoue K. 2006) leads to BDNF release and 
IL1β synthesis, respectively. Inhibition of P2X4 after nerve injury alleviates 
mechanical allodynia and prevents upregulation of P2X4 in the dorsal horn. Genetic 
deletion of the P2X7 receptor resulted in decreased neuropathic pain, but it is not 
clear whether this effect is mediated specifically by microglia or includes 
involvement of other central or peripheral cell types (Borzan J., Meyer R.A. 2009). 
Fractalkine (CX3CL1), for example, is expressed by neurons and astrocytes, 
whereas its receptor CX3CR3 is expressed on microglia, suggesting a signaling role 
by the chemokine between these cells (Milligan F.D. et al. 2008). CCL2 (MCP-1) 
and its receptor CCR2 are both up-regulated in the DRG and distributed to the spinal 
cord after nerve injury (White F.A. et al. 2007). Intrathecal administration of 
CX3CL1 or CCL2 produces pain in näıve animals, while their neutralization 
prevents neuropathic pain hypersensitivity (Abbadie C.2005, Watkins L.H. et al. 
2007).  
Neuronal release of chemokine fractalkine activates spinal microglia via 
CX3CR1 receptor and causes activation of the MAPK p38 pathway. Nerve injury 
also leads to activation of Src kinase in microglia but not neurons or astrocytes. 
Spinal inhibition of Src kinase attenuates mechanical allodynia by inhibiting 
extracellular signal-regulated protein kinase. Increased levels of proinflammatory 
cytokines have been observed in the spinal cord tissue following peripheral nerve 
injury. Additionally, intrathecal delivery of cytokine inhibitors can lead to the 
reduction of neuropathic pain (Borzan J., Meyer R.A. 2009). 
Another example for neuronglia interactions contributing to neuropathic pain 
are the matrix metalloproteinases MMP2 and MMP9. They are produced by both 
neurons and glia and mediate pain hypersensitivity by initiating IL1β cleavage and 
microglial and astrocytic activation (Kawasaki Y. et al. 2008). Inhibition of immune 
function represents a major avenue for therapeutic intervention for neuropathic pain 
(Fig. 8) 
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Figure 8 Immune cells present or recruited in the central (a) and peripheral (b) nervous 
system following nerve injury influence the excitability of primary afferents and second-
order neurons.  
TNF-α, tumor necrosis factor-a; IL-1b, interleukin-1b; IL-6, interleukin-6; NO, nitric oxide; PGs, ATP 
and prostaglandins; AMPA, a amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; CCR2, CCL2 
receptor (CX3CR1), fractalkine receptor; EAA, excitatory amino acids; ERK, extracellular signal-
regulated kinase; FPRL1, formyl peptide receptor-like 1; MHC, major histocompatibility complex; 
NGF, nerve growth factor; NK1R, neurokinin-1 receptor; NMDA, N methyl-Daspartate; P2X4 and 
P2X7, ionotropic purinoceptors; p38 MAPK, p38 mitogen-activated protein kinase; TLR4, toll-like 
receptor 4; CCL2, chemokine (C–C motif) ligand 2. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Neuroscience (Marchand F, Perretti M, and McMahon SB (2005) 
Role of the immune system in chronic pain. Nature Reviews Neuroscience 6: 521–532), copyright 
2005. 
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1.2.4    Affective component of neuropathic pain 
 
Pain is a complex sensory and emotional experience that can vary widely 
between people and even within an individual depending on the context and meaning 
of the pain and the psychological state of the person. Cognitive and emotional factors 
have a surprisingly important influence on pain perception. A negative expectation 
can completely reverse the analgesic effect of a clinical dose of the opioid agonist 
remifentanil (Bingel U. et al 2001), whereas the expectation of pain relief is an 
important component of placebo analgesia (Benedetti F. et al. 2005). Our emotional 
state has an enormous influence on pain; a negative emotional state increases pain, 
whereas a positive state lowers pain (Villemure C., Bushnell, M.C. 2009). 
 Imaging studies show that psychological factors activate intrinsic modulatory 
systems in the brain, including those involved in opioid-related pain relief. 
Furthermore, multiple descending pain modulatory systems are implicated in pain 
relief, with attentional states and emotions activating different systems in the brain.  
In parallel with increased understanding of the circuitry underlying the psychological 
modulation of pain, recent evidence shows that chronic pain can lead to anatomical 
and functional alterations in this same circuitry, resulting not only in pain but also in 
altered cognition and affect. The wealth of new studies showing alterations in the 
brains of patients with chronic pain can now be integrated with our increased 
understanding of the brain circuitry involved in the psychological modulation of 
pain, allowing us to hypothesize a negative-feedback loop between impaired pain 
modulatory circuitry and pain processing, leading not only to increased chronic pain 
but also to cognitive and emotional deficits that are comorbid with the pain (Fig. 9) 
(Bushnell M.C. et al. 2013). 
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Figure 9 Feedback loops between pain, emotions and cognition. Pain can have a 
negative effect on emotions and on cognitive function. Conversely, a negative emotional state can lead 
to increased pain, whereas a positive state can reduce pain. Similarly, cognitive states such as attention 
and memory can either increase or decrease pain. Of course, emotions and cognition can also 
reciprocally interact. The minus sign refers to a negative effect and the plus sign refers to a positive 
effect (Bushnell M.C. et al. 2013). 
.  
 
Neuroimaging studies have now identified several cortical regions in humans 
that are considered to be important for the perception of pain. The primary and 
secondary somatosensory cortices (insular and anterior cingulate) and the prefrontal 
cortices (PFCx) are commonly activated, often bilaterally, and during painful 
experiences. Furthermore, altered activity in subcortical areas (e.g. brainstem 
periaqueductal grey (PAG), hypothalamus, amygdala, hippocampus, and cerebellum) 
is also observed during pain. Thus, activity within several diverse regions of the 
brain seem to be necessary for the multidimensional experience that is pain 
(Apkarian A.V. et al 2009, Apkarian A.V. et al 2005). Some of these regions 
comprise the so-called ‘pain neuromatrix’(Melzack R. 2001), in which multiple 
inputs are processed to produce an output (neurosignature) that is bespoke for an 
individual depending on context, mood and cognitive state (Tracey I., Mantyh P.W. 
2007) Hence, pain is the product of a widely distributed and variably accessible 
neural network in the brain, rather than an inevitable consequence of noxious 
stimulation. 
Perception is singular psychological construct, with a complex physiological 
phenomenon in the brain, as that of consciousness. The mode of pain perception can 
be defined in three distinct conceptual stages related to different functional neuraxis 
areas: (1) sensory transmission at the brainstem area, also acting in descending 
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regulation, and the thalamic relay nuclei, while sensory discrimination of 
spatial/temporal features in primary somatosensory cortex; (2) affect transaction at 
the secondary somatosensory cortex, insular cortex, amygdala and hippocampus 
cortices for aversive learning, visceral nociception, and autonomic effect; (3) 
cognitive attention at the anterior cingukate cortex, prefrontal cortex, as well in 
response selection or action planning. Transmission of sensory nociception is largely 
considered as serial processing from brainstem, thalamus , primary somatosensory 
cortex and secondary somatosensory cortex. This sensory-perceptual system 
participates in the cerebral functions of detection, localization, timing, learning, 
relay, integration, ascending transmission and descending regulation of pain. The 
transaction of painful emotion is probably considered as parallel processing at sites 
of insular cortex , amygdala , hippocampus , hypothalamus and cingular cortex . This 
affective-motivational system participates in the functions of affective reaction, 
visceral activation, multi-sensory integration, homeostasis regulation, fear and 
memory. Translation of painful cognition is assumed to be carried out by the 
integration of several cortical areas in prefrontal cortex, primary motor cortex, 
supplementary motor cortex and posterior parietal cortex. This cognitive evaluation 
system participates in the functions of executive control, coordination of 
action/intention and spatial/bodily attention (Chen A.C. 2008). 
Neuropathic pain has been described as the “most terrible of all tortureswhich 
a nerve wound may inflict” (Jaggi A.S., Singh N. 2001). 
Chronic pain induces mood disorders, including depression and anxiety. In 
addition, the adverseness of pain is amplified or reduced depending on the emotional 
environment, and conditions of increased anxiety and depression are usually 
associated with decreased pain tolerance. This vicious circle may trigger, or even 
result from, neuronal changes (Goncalves L. et al. 2008). 
Different work in both human patients and laboratory animals has 
demonstrated that the presence of chronic neuropathic pain causes gross 
reorganization and functional changes in both cortical and subcortical structures, 
including the medial prefrontal cortex (Baliki M.N. et al. 2006, 2008; Metz A.E. et al. 
2009), thalamus (Apkarian A.V. et al. 2004a), amygdala (Han V., Neugebauer J.S. 
2005; Ji G. et al., 2010), and anterior cingulate cortex (Li X.Y. et al. 2010). These 
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areas are associated with functions including learning, memory, fear, and emotional 
responses and map on to cognitive and emotional problems suffered by chronic pain 
patients, such as elevated anxiety and depression (Gore M. et al. 2011), problems in 
emotional decision making (Apkarian A.V. et al. 2004b), working memory (Dick 
B.D., Rashiq S. 2007), and difficulty in classical conditioning tasks (Flor H. et al. 
2002)(Mutso A.A. et al. 2012). 
 
 
1.3 Endogenous Opioid System 
 
Opioid receptors and their endogenous peptide ligands are largely distributed 
through the CNS and peripheral tissues. This wide distribution is related to the 
important role that the opioid system plays in the control of several physiological 
responses including nociception, emotional behavior, learning and memory and 
regulation of reward circuits. 
The existence of membrane receptors in the brain for opiate drugs was shown 
for the first time in 1973 by three independent groups (Pert C.B., Snyder S.H. 1973; 
Simon E.J. et al. 1973; Terenius L. 1973). A few years later, different opioid binding 
sites were identified, confirming that opioid receptors did not constitute a 
homogenous population (Lord J.A. et al. 1977; Martin W.R. et al. 1976). The 
knowledge of the Endogenous Opioid System was largely improved since the 
molecular characterization and cloning in the mid 1990s of the different opioid 
receptors µ, δ and κ (Chen Y. et al. 1993; Evans C.J. et al. 1992; Kieffer B.L. et al., 
1992; Meng F. et al. 1993; Thompson R.C. et al. 1993; Yasuda K. et al. 1993). 
In addition to the well-established three types of opioid receptors, an orphan 
opioid-like receptor (ORL1) was cloned in 1994. This receptor has nearly 70% 
sequence homology with the opioid receptors. The endogenous ligand for the ORL1 
receptor was isolated and named nociceptin or orphanin FQ (Meunier J.C. 1995; 
Reinscheid R.K. et al. 1995). 
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1.3.1 Opioid Peptides 
 
Three families of endogenous peptides enkephalins, dynorphins and β-
endorphin derive from proenkephalin (PENK), prodynorphin (PDYN) and 
proopiomelanocortin  (POMC), respectively. PENK is the source of [Met5]-  and 
[Leu5]-enkephalins and several longer peptides. Endogenous opioid peptides such as 
dynorphin A, dynorphin B and α- and β-neoendorphin and several larger molecules 
can be generated from PDYN. POMC is the precursor of β-endorphin, α-endorphin 
and several non opioid peptides. The endogenous opioid peptide-containing neurons 
have been found in the regions involved in the nociceptive response, e.g. the 
thalamus, periaqueductal grey, limbic system, cortex and in the spinal cord. 
Similarly, the autonomic nervous system centers have been shown to be innervated 
by central and peripheral opioidergic neurons (Przewłocki R., Przewłocka B. 2001). A 
novel group of peptides has been discovered in the brain and named endomorphins, 
endomorphin-1 (Tyr–Pro–Trp–Phe–NH2) and endomorphin-2  (Tyr–Pro–Phe–Phe–
NH2). They are unique in comparison with other opioid peptides, having a 
characteristic atypical structure and high selectivity towards the µ-opioid receptor 
(Zadina J.E. et al. 1997). Anatomical studies demonstrated a distinct anatomical 
distribution of endomorphins (e.g. endomorphin-1 is present mainly in the brain and 
endomorphin-2 in the spinal cord) and their synthesis in separate cellular systems. 
Another system which has joined the endogenous opioid peptide family is the 
pronociceptin system comprising the peptides derived from this prohormone, acting 
at ORL1 receptors (Meunier J.C. 1995; Reinscheid R.K. et al. 1995) (Fig.10). 
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Figure 10 Proopiomelanocortin, preproenkephalin A, preproenkephalin B, and 
preproorphanin FQ (prepronociceptin) precursor molecules and their related cleavage 
products: ACTH, β-lipotropin (B-LPH), α-melanocyte-stimulating hormone (α-MSH), 
corticotropin-like intermediate lobe peptide (CLIP), γ-LPH, β-endorphin, met-enkephalin, 
leu-enkephalin, dynorphin A, neoendorphin, and orphanin FQ (nociceptin) (James H. Liu and 
John L. Mershon, Neurosecretory Peptides). 
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1.3.2 Opioid Receptors 
 
Opioid receptors belong to the superfamily of seven transmembrane domain 
receptors and produce their cellular effects via coupling with toxin-sensitive GTP-
binding proteins Gi/Go (Fig 11). Activation of opioid receptors leads to inhibition of 
cAMP production and voltage gated Ca2+ channels, as well as the stimulation of 
inwardly rectifying K+ channels and activation of the MAP kinase pathway. At 
cellular level, all these actions induce inhibition of neuronal activity and a reduction 
in neurotransmitter release (Law P.Y. et al. 2000).  
The cloned µ-opioid receptor is a morphine-like receptor, and endomorphins may be 
its endogenous ligands. The enkephalins bind to the δ-opioid receptor with great 
affinity, and therefore, are considered to be endogenous δ-opioid receptor agonists. 
The affinity of β-endorphin binding to µ- and δ-opioid receptors was found to be 
similar. Dynorphins bind to k-opioid receptors and therefore appear to function as its 
endogenous ligands. Opioid peptides do not bind exclusively to one specific receptor 
type but have some affinity for other opioid receptors as well (Przewłocki R., 
Przewłocka B. 2001). Several subtypes of the opioid receptors (µ1, µ2; δ1 δ2; κ1, κ2, 
κ3) have been postulated on the basis of  pharmacological studies. Cloning of all 
opioid receptors to date yielded a single receptor type, and the suggested subtypes 
are possibly alternative splicing products. In addition, oligomerization of various 
opioid receptors generates unique functional properties (Jordan B.A.,Devi L.A. 
1999). 
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Figure 11 Representation of the opioid receptor structure, constituted by seven 
transmembrane domains, an extracellular site for interaction with the ligand and an 
intracellular site for interaction with the G protein of inhibitory (G i / o). 
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1.3.3 Nociceptin – NOPr system 
 
1.3.3.1 NOP receptor 
 
The NOP receptor was first cloned as an orphan opioid receptor-like receptor 
from human (Mollereau C. et al. 1994)  rat (Bunzow J.R. et al. 1994) , and mouse 
(Nishi M. et al. 1994) brain, and human lymphocytes (Halford W.P. et al. 1995; Wick 
M.J. et al. 1994). NOP  is a typical G-protein-coupled receptor with seven predicted 
transmembrane domains (Fig. 12). 
 
 
        
 
Figure 12 The NOP receptor. 
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Alignment of the cDNA-deduced amino acid sequences of the human NOP, 
δ-, µ-, and κ-opioid receptors reveals conserved regions, notably in the 
transmembrane helices and cytoplasmic loops (Fig. 13). Sequence conservation 
among the four receptors is highest (>70%) in the second, third, and seventh 
transmembrane helices, and approximately 50% in the first, fifth, and sixth, but 
significantly lower (24%) in the fourth. Amino acid sequence identity is also high 
(56–86%) in the four intracellular loops. All other regions, the C-terminal half of the 
first exofacial loop excepted, display little amino acid sequence conservation. While 
the e2 loops of the ORL1, m-, and d-opioid receptors are all of the same length, the 
highly acidic content of the ORL1 e2 loop is retained only in the k-opioid receptor 
loop, which contains two insertion sites and is three residues longer. It is also 
apparent that the charge distributions as a linear function of residue position in the k-
opioid and ORL1 receptor e2 loop sequences are quite dissimilar (Meunier J.C. et al. 
2000). Despite their close homology to the other opioid receptors, only few opioids 
bind these novel clones, and their affinities are markedly lower than those seen with 
the other opioid receptors. 
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Figure 13 Sequence alignment of the putative opioid receptor with three other opioid 
receptors. The ammo acids identical to the putative opioid receptor  are marked by a dash (-). The 
seven putative hydrophobic transmembrane domains are underlined and labeled from TM1 to TM7. 
Gaps are  introduced for alignment. Other symbols: (=), the conserved cysteine residues possibly 
involved with disulfide bond formation; (*), the conserved aspartic acid residues that may interact 
with the primary amine group found in ligands; (^), the potential N-linked glycosylation sites; (S), the 
putative  protein kinase C sites; (o), the potential CAMP dependent protein kinase site; (#), the 
potential pahnitoylation site (Chen Y. et al. 1994). 
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The receptor has three coding exons, similar to the other opioid receptors. The first 
coding exon yields the amino terminus and the first transmembrane domain. The 
second coding exon is responsible for the next three transmembrane domains. The 
splice site between the second and third coding exons is located in the second 
extracellular loop, and the third coding exon is responsible for the remainder of the 
protein, including the last three transmembrane domains and the intracellular 
carboxyl tail. The binding pocket has been proposed to comprise several of the 
transmembrane domains (Topham et al. 1998; Mouledous et al. 2000). The initial 
gene structure identified five exons, with a noncoding exon preceding and following 
the three coding exons; other work has identified two mini-exons between the first 
and second coding exons that are alternatively spliced for a total of seven (Mogil J.S., 
Pasternak G.W. 2001). 
The regional distribution of  NOP receptor have been well described (Bunzow J.R. et 
al. 1994; Fukuda K. et al. 1994; Mollereau et al., 1994; Wick et al. 1994; Lachowicz 
J.E. et al. 1995). Regions with NOP1 receptor binding typically express NOP1 
mRNA as well, although the levels of mRNA and binding do not always match very 
closely. Regions with high levels of NOP1 binding/mRNA include the cortex, 
anterior olfactory nucleus, lateral septum, hypothalamus, hippocampus, amygdala, 
central gray, pontine nuclei, interpeduncular nucleus, substantia nigra, raphe 
complex, locus coeruleus, and spinal cord (Mogil J.S., Pasternak G.W. 2001). 
 
 
1.3.3.2  Nociceptin 
 
N/OFQ is a heptadecapeptide with some interesting structural homologies to 
the classical opioid peptide dynorphin A (Fig 14). Both peptides are comprised of 17 
amino acids bounded by pairs of basic amino acids important in their production 
from their precursors. Furthermore, both have internal pairs of basic amino acids, 
raising the possibility of further processing. The opioid peptides share a YGGF 
motif, where the fifth amino acid is either leucine or methionine. The amino terminus 
of N/OFQ is a phenylalanine instead of a tyrosine, followed by GGF. Finally, both 
peptides contain the same last two amino acids at the carboxyl terminus. Despite 
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these similarities, the peptides are functionally quite distinct. N/OFQ has no 
appreciable affinity for any of the opioid receptors (Mogil J.S., Pasternak G.W., 
2001). 
 
 
a) 
      
 
 
b) 
           
 
Figure 14  a) Three-dimensional representation of the nociceptin. 
       b) Structure of Nociceptine compared with some Opioid Peptides 
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Like all bioactive peptides, N/OFQ is generated from a larger precursor peptide, 
prepro N/OFQ (ppN/OFQ) that has been cloned from mouse, rat, and human (Fig. 
15) (Meunier et al. 1995; Pan Y-X et al. 1996a; Reinscheid R.K. et al. 2000). 
Overall, there is high interspecies homology, with 80% identity among the three 
organisms. 
 
   
 
 
 
Figure 15 Schematic of the prepro-OFQ/N gene (Mogil J.S., Pasternak G.W., 2001). 
 
 
 
The primary structure of the precursor protein contains the typical structural 
elements of a neuropeptide precursor. It starts with an amino terminal signal peptide 
necessary for its secretion. The N/OFQ sequence is flanked by pairs of Lys-Arg 
residues, indicating that its maturation requires trypsin-like cleavages. The C-
terminus of the precursor protein downstream of the N/OFQ sequence is conserved 
among the different species genes and could generate either a 28- residue long 
peptide or, after cleavage at the Arg triplet, a 17-residue long peptide, whose 
terminal amino acids are the same as these of N/OFQ. These two peptides were 
synthesized but were unable to either bind or activate the NOP receptor (Civelli O. 
2008). It has been reported that the 17-amino acid peptide (termed NocII or OFQ II) 
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exhibits some effect on locomotion and pain perception (Florin S. et al. 1997; Rossi 
G.C. et al. 1998).  
The bovine precursor harbors an additional pair of basic amino acids N-
terminal to the N/OFQ sequence that could give rise to a 19-amino acid peptide 
(Okuda-Ashitaka E. et al. 1998). This putative was isolated from bovine bran and has 
been reported to possess an anti-N/OFQ activity because it was able to block N/OFQ 
induced allodynia and hyperalgesia (Okuda-Ashitaka E. et al. 1998). This peptide 
was named nocistatin and acts via a receptor different from the NOP receptor. The 
active part of nocistatin was found to reside in its C-terminal hexapeptide that is also 
the only conserved structure between all mammalian N/OFQ precursors. The bovine 
form of nocistatin appears to be species-specific because the human, rat, mouse, and 
porcine precursor lack the pair of basic amino acids that is used for processing in the 
bovine precursor protein. The fact that OFQ II or nocistatin require their own 
receptors but that none have been identified that would exhibit selectivity for these 
two peptides indicate that these peptides may not be neuropeptides that act through a 
traditional GPCR system (Civelli O. 2008). 
The localization of N/OFQ corresponds reasonably well with the NOP1 
receptor. As with the receptor, N/OFQ immunoreactivity and mRNA levels detected 
using in situ hybridization are closely correlated. N/OFQ is found in lateral septum, 
hypothalamus, ventral forebrain, claustrum, mammillary bodies, amygdala, 
hippocampus, thalamus, medial habenula, ventral tegmentum, substantia nigra, 
central gray, interpeduncular nucleus, locus coeruleus, raphe complex, solitary 
nucleus, nucleus ambiguous, caudal spinal trigeminal nucleus, and reticular 
formation, as well the ventral and dorsal horns of the spinal cord (Neal C.R. et al. 
1999). 
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1.3.3.3   Pharmacological Effects of Nociceptin/Orphanin FQ  
 
The N/OFQ receptor was shown to induce a variety of intracellular effects. 
First N/OFQ receptor was shown to induce an inhibition of adenylyl cyclase in CHO 
cells transfected with the NOP receptor (Meunier et al. 1995; Reinscheid et al. 
1995). Next, N/OFQ was found to modulate cellular excitability increasing inwardly 
rectifying K-conductance in dorsal raphe nucleus neurons (Vaughan C.W., Christie 
M.J. 1996) and in the arcuate nucleus (Wagner E.J. et al. 1998); to increase K-
conductance in periaqueductal gray neurons (Vaughan et al. 1996) and in locus 
coeruleus neurons; to couple to G protein-activated K channels; to inhibit voltage-
gated calcium channels in freshly dissociated CA3 hippocampal neu- rons; to inhibit 
T-type Ca channels in sensory neurons; and to inhibit N-type Ca channels in SH-
SY5Y cells. Also, the N/OFQ receptor appears to couple to K channels in Xenopus 
oocytes. Furthermore, N/OFQ has been shown to inhibit the release of glutamate and 
GABA from nerve terminals, to block acetylcholine release from retina and 
parasympathetic nerve terminals, to inhibit synaptic transmission and long-term 
potentiation in the hippocampus, to suppress dopamine release in the nucleus 
accumbens, and to inhibit tachykinin and calcitonin gene-related peptide release from 
sensory nerves. N/OFQ was demonstrated to activate mitogen-activated protein 
kinase in re- ceptor transfected CHO cells. Together, these results show that N/OFQ 
is able to modulate the biochemical properties of cells, alter the electrophysiological 
properties of neurons and to affect their transmitter reease. Importantly, none of the 
effects of N/OFQ described were inhibited by opiate antagonists, emphasizing the 
pharmacological difference between the opioid and the N/OFQ systems (Civelli O. 
2008).  
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1.3.3.4 Nociceptin and pain 
 
There is a wealth of evidence showing that N/OFQ has pronociceptive and 
antinociceptive effects depending on the drug dose, test, and route/side of injection 
used. N/OFQ at low doses in the pmol and fmol ranges displays pronociceptive 
action, whereas N/OFQ exhibits antinociceptive potential when administered at 
higher doses in the nmol range, (Mogil J.S., Pasternak G.W. 2001; Yamamoto T. et 
al. 1999; Tab, 3 Prezwloka). Both effects induced by N/OFQ have been suggested to 
be mediated by the NOP receptor.  
 
 
 
 
Table 3  A comparison of the effects induced by application of nociceptin and dynorphin on 
acute pain sensitivity and motor function/activity (Mika J. et al. 2011). 
 
 
In behavioral studies, intracerebroventricular (i.c.v.) administration of N/OFQ was 
found to display hyperalgesic effects that are observed as reduced latencies in the hot 
plate test (Meunier et al. 1995; Suaudeau C. et al. 1998) and the tail-flick test 
(Suaudeau C. et al., 1998; Reinscheid R.K. et al. 1995) and as decreased locomotor 
activity in mice (Reinscheid et al., 1995). Also, N/OFQ that was microinjected into 
the periaqueductal gray increased pain sensitivity in rats (Wang H. et al., 1998). 
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These effects were likely mediated by the NOP receptor based on the results of a 
study that has shown that the pronociceptive action of N/OFQ is not present in NOP 
knockout mice and that antisense oligonucleotides targeting the NOP receptors 
prevent the N/OFQ effect (Calo G. et al. 2000). On the other hand, it was 
demonstrated that N/OFQ administered i.c.v. in the nmol dose range was ineffective 
in significantly altering the response to noxious stimuli (Zhu C.B. et al. 1998; 
Vanderah T.W. et al. 1998). Although a consensus on the precise function of N/OFQ 
in the modulation of nociception has not been reached, a large body of evidence 
indicates that supraspinal injection of N/OFQ does not affect pain sensitivity (Grisel 
J.E. et al. 1996). Interestingly, it has also been suggested that the pronociceptive 
effects produced by i.c.v. administration of N/OFQ may provide an explanation for 
the anti-opioid action of N/OFQ (Mogil et al., 1996). This phenomenon was 
confirmed by experiments demonstrating that N/OFQ was able to alter the analgesic 
effectiveness of morphine and other opioids.  
In contrast to the pronociceptive effects induced by i.c.v. injection of N/OFQ, at the 
spinal level, i.t. administered N/OFQ generally has been found to produce 
antinociceptive responses that are similar to classical opioid receptor agonists 
without inducing signs of sedation or motor impairment (tab. 3). However, i.t. 
N/OFQ at doses lower than those exhibiting analgesic potential induced 
hyperalgesia, allodynia and impaired locomotor activity. Thus, N/OFQ at low doses 
in the pmol and fmol ranges displayed pronociceptive action resulting from the 
activation of NOP receptors at the spinal level and exhibited antinociceptive potential 
at higher, nmol doses. However, it should also be noted that some authors reported 
that N/OFQ applied i.t. at nmol doses had no effect by itself. Interspecies and even 
interstrain differences, disparate doses and different testing procedures may ac- count 
for the conflicting results reported with N/OFQ and other NOP receptor ligands in 
the spinal cord (Mika J. et al. 2011).  
 It has been clearly documented that the induction of chronic pain states, especially 
neuropathy, is associated with an upregulation of N/OFQ synthesis, as indicated by 
enhanced expression of pN/OFQ protein and/or mRNA (Dubner and Ruda, 1992; 
Kajander et al., 1990; Malan et al., 2000; Mika et al., 2010; Fig. 16).  
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Figure 16 A comparison of the changes in the levels of mRNA and/or protein for nociceptin 
(N/OFQ), dynorphin (DYN), nociceptin-opioid peptide (NOP) receptor and kappa-opioid 
peptide (KOP) receptor in the ipsilateral part of the dorsal spinal cord and ipsilateral dorsal 
root ganglia under neuropathic pain conditions (Mika J. et al. 2011). 
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Many studies have supported the suggestion that the analgesic effectiveness of the 
N/OFQ and NOP receptor ligands is increased in neuropathic conditions and that this 
effect is associated with upregulation of NOP receptor mRNA in the spinal cord and 
DRG after nerve injury. Moreover, at the spinal level, it is well-documented that 
N/OFQ produces antinociception through presynaptic (DRG) and postsynaptic 
(spinal cord) mechanisms. The increase in N/OFQ in DRG neurons after axotomy as 
well as after sciatic nerve ligation  is potentially related to the enhanced spinal 
N/OFQ release from afferent neurons and, therefore, may be an additional factor in 
this regulatory circuit. This effect is in contrast to the classical opioid receptor 
agonists, such as morphine, which are less effective in neuropathy than in acute pain 
conditions. Behavioral experiments have demonstrated that N/OFQ administered i.t. 
alleviates allodynia and hyperalgesia resulting from injury of the sciatic nerve (Mika 
J. et al. 2011). 
 
 
1.3.3.5  Anxiety, stress and depression 
 
The observation that N/OFQ is able to reverse stress-induced analgesia 
(Mogil J.S. et al. 1996) and that the NOP receptor is expressed in brain centers 
known to modulate anxiety prompted investigations into the effects of N/OFQ on 
stress as it relates to anxiety. Central administration of N/OFQ was found to exert 
profound anxiolytic effect comparable to classic anxiolytic drugs such as diazepam 
(Jenck F. et al. 1997). Low nanomolar doses of N/OFQ decreased behavioral 
measures of anxiety in rats using the light–dark box and elevated plus maze 
paradigms. Similar to the biphasic effect of diazepam, higher doses of N/OFQ also 
showed motor impairment. These findings were later confirmed with mice in the 
elevated plus maze paradigm (Gavioli E.C. et al. 2002) or the hole-board exploration 
test (Kamei J. et al. 2004) and in the defense test battery (Griebel G. et al. 1999), 
although in the latter paradigm, the effects were observed only after very high stress. 
Altogether, these experiments provided evidence that the N/OFQ system might be 
involved in modulation of stress as it relates to anxiety. The mechanism by which the 
N/OFQ system modulates stress is not fully understood but implicates regulation of 
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the hypothalamic–pituitary–adrenal (HPA) axis. N/OFQ KO mice exhibit elevated 
plasma corticosterone levels under both resting and post-stress conditions 
(Reinscheid R.K., Civelli O. 2002), and N/OFQ administrations reverse transient 
increases in plasma corticosterone precipitated by stressors such as 
intracerebroventricular injections.  
The first indication that the N/OFQ system may be involved in modulating 
depressive states of behavior came from the observation that rat pups who were 
separated from their mothers exhibit elevated levels of N/OFQ expression in 
adolescence. That the N/OFQ system may have a role in depression-like symptoms is 
further indicated by the finding that N/OFQ levels are elevated in postpartum 
depressive women but, more importantly, by studies that showed that N/OFQ 
antagonists could produce antidepressant effects, such as reduced immobility time in 
the mouse forced-swim test, which reflects behavioral despair. Moreover, NOP KO 
mice also display reduced immobility time in the same assay. The mechanism for the 
antidepressive effects of N/OFQ antagonists is unknown. N/OFQ is able to attenuate 
serotonin release from dorsal raphe neurons and rat cortical serotonergic terminals, 
thus acting to reduce serotonin levels. Conversely, N/OFQ antagonists are able to 
block the N/OFQ-induced inhibition of noradrenaline and serotonin release from 
cortical synaptosomes (Civelli O. 2008).  
 
 
 
 
 
 
 
 
 
 
 
  
 
56 
 
1.3.4 Dynorphin system 
 
Dynorphin system is part of Endogenous Opioid System including the 
dynorphin (DYN) peptide and his receptor KOP. This system is widely involved in 
neuropathic pain, but its role is complex and not completely clear yet. 
 
 
1.3.4.1 Dynorphin 
 
In 1979, Goldstein A. et al. 1979 described the opioid properties of a 
tridecapeptide, which they had first isolated from porcine pituitary four years earlier 
(Cox B.M. et al. 1975; Teschemacher H. et al. 1975). The first five amino acids of 
this peptide (Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile- Arg-Pro-Lys-Leu-Lys) represent 
Leu-enkephalin. To denote its extraordinary potency, the natural peptide was named 
“dynorphin” from the Greek dynamis=power and the ending  orphin indicating its 
opioid nature. Two years later, the complete sequence of 17 amino acids was 
identified (Goldstein A. et al. 1981) (Fig. 17) This peptide was renamed to dynorphin 
A after the isolation of the larger form dynorphin-32 which consists of the original 
17 amino acids at its amino-terminus and a novel Leu-enkephalin containing 
tridecapeptide now termed dynorphin B (=rimorphin) at the carboxy-terminus. The 
two peptides are linked by a pair of basic amino acids (Lys-Arg), which indicate a 
potential processing site (Fischli W. et al. 1982a,b). A smaller bioactive form of 
dynoprhin A, dynorphin 1-8, was described in 1980 (Minamino N. et al. 1980). The 
first five amino acids (i.e. those representing Leu-enkephalin) were proposed as 
essential for binding to opioid receptors (Chavkin C., Goldstein A. 1981). 
Characterization of the precursor of dynorphins (Dyn), prodynorphin (pDyn, also 
termed proenkephalin B) at the mRNA (Kakidani H. et al.1982) and protein level 
(Watson S.J. et al. 1983) also revealed the presence of α- and β-neoendorphin 
(Minamino N. et al. 1981), leumorphin (=dynorphin B 1-29; assembled from 
dynorphin B and the C-terminal C-peptide) as well as a number of biologically 
inactive fragments, which do not contain the Leu-enkephalin motif. 
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DYN have increasingly been thought to play a regulatory role in numerous 
functional pathways of the brain. In line with their localization in the hippocampus, 
amygdala, hypothalamus, striatum and spinal cord, these functions are related to 
learning and memory, emotional control, stress response and pain. 
Pathophysiological mechanisms that may involve DYN/kappa opioid receptors 
(DYN/KOP) include epilepsy, addiction, depression, schizophrenia, and chronic pain 
(Schwarzer C. 2009). 
 
 
 
 
 
 
 
Figure 17   3D structure of  DYN A (1-17) 
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1.3.4.2  Dynorphin gene and mRNA 
 
The pDYN gene contains four exons (1–4) and three introns (A,B,C) in 
humans and rodents (Horikawa S. et al. 1983; Douglass J. et al. 1989; Sharifi N. et 
al. 1999). While exons 1 and 2 encode for the majority of the 5′-untranslated region, 
exons 3 and 4 contain the entire coding sequence (Fig. 13) (Schwarzer C. 2009). 
Several promoter elements have been identified within the rat pDYN promoter. The 
four CRE sites observed in the rat promoter were thought to be the most important, 
perhaps being responsible for the excitation-dependent regulation of pDYN 
expression (Douglass J. et al. 1994). In terms of suppression of pDYN expression, 
the downstream regulatory element (DRE) and its Ca2+-regulated transcriptional 
repressor DREAM was suggested to be important (Carrion A.M. et al. 1999; Campos 
D. et al. 2003). DREAM appears to play a crucial role in the regulation of pDYN 
expression in neuropathic and inflammatory pain. Low concentrations of DYN acting 
on KOP located on spinal projection neurons produce analgesic effects. In contrast, a 
single intrathecal injection of a higher dose of DYN produces long-lasting allodynia 
in mice and rats. This puzzle was solved by identification of NMDA receptors as 
target of high concentrations of DYN (Vanderah T.W. et al. 1996; Laughlin T.M. et 
al. 1997). Noteworthy, knockout of DREAM, leading to increased expression of 
pDyn markedly reduces a broad spectrum of acute and chronic pain related 
behaviours (Cheng H.Y. et al. 2002).  
Seven pDYN mRNA splice variants have been isolated from human brain 
(Horikawa S. et al. 1983; Telkov M. et al. 1998; Nikoshkov A. et al. 2005). Two of 
the transcripts, termed FL1 and FL2, contain the entire coding sequence of pDYN 
(Fig. 18). The predominant form FL1 is highly expressed in limbic structures such as 
the nucleus accumbens and amygdala, while the expression of FL2 is restricted to a 
few brain areas including the claustrum and hypothalamus (Nikoshkov et al., 2005). 
These two transcripts differ in their 5′-non-coding region. FL1 transcripts are 
initiated somewhat upstream of the proposed transcription initiation site (Douglass J. 
et al. 1994). FL2 contains a novel second exon, which extends the originally 
described exon 2 and is initiated within intron A close to a site previously detected in 
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embryonic brain (Telkov M. et al. 1998). The exons comprising FL1 and FL2 are 
highly conserved in human, mouse and rat genomes (Schwarzer C. 2009). 
 
 
1.3.4.3   Processing of Dynorphin  
 
Like all other neuropeptides, DYN are processed from a large biologically 
inactive precursor protein. The first evidence for differential processing of pDYN 
was observed in the lobes of the pituitary. Processing of pDYN requires the 
endopeptidases, termed prohormone convertases (PC), PC1 and PC2 and 
carboxypeptidase E (Fig.18). PC1 was proposed to cut at the carboxy side of three of 
the seven pairs of basic amino acids. The primary target is the Lys-Arg pair N-
terminal to α- neoendorphin, yielding a 10 kDa C-terminal fragment containing all 
known pDYN-derived peptides (Fig. 18). A minor alternative pathway may be the 
proteolytic cleavage at the Lys-Arg pair C-terminal to α-neoendorphin. In a second 
step, a carboxyterminal fragment of about 2 kDa is cleaved at a single Arg, yielding 
an 8 kDa intermediate product (Dupuy A. et al. 1994). Further processing requires 
PC2, producing biologically active peptides including α-neoendorphin, big- DYN, 
leumorphin, DYN A 1-17 and 1-8 and DYN B (Fig.13). This processing is enhanced 
by the presence of carboxypeptidase E (Day R. et al. 1998).  
In vitro studies on the ability of different pDyn-derived peptides to activate kappa 
opioid receptors suggested a rank order of potency with Dyn A1-17 > (10–20 times) 
big- DYN=DYN B=DYN B 1-29=α-neo-endorphin>(10–20 times) Dyn A 1-8 = β 
neo-endorphin (James I.F. et al. 1984). Differential processing of pDyn was also 
observed in the brain. Electron microscopy showed the coexistence of pDyn and Dyn 
within the same axon and even individual vesicles (Yakovleva T. et al. 2006). While 
the classical model suggests initiation of processing of pDYN in the trans-Golgi 
network, a newly hypothesized model suggests transport of pDYN to the synapse and 
initiation of processing in response to external stimuli. Such a regional regulation of 
trafficking and processing at synapses may provide local regulation of synaptic 
transmission (Yakovleva T. et al. 2006) (Schwarzer C. 2009). 
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Figure 18  Biosynthesis of pDYN derived peptides. The entire coding sequence of pDYN is 
contained in exons 3 and 4 (dark grey shading) of the pDYN gene.  
Several differentially spliced transcripts are derived from this single gene, however only the two full-
length mRNAs FL1 and FL2 are found in humans and rodents. These two splice variants differ only in 
the 5´- non-coding region with FL2 being transcribed from an extended exon 2 (light grey). An 
identical 254-amino acid preprodynorphin is translated from both mRNAs. The first 20 amino acids 
represent the signal peptide, responsible for targeting the protein towards the endoplasmatic reticulum. 
This peptide is immediately cleaved by the signal peptidase, resulting in pDYN. Further processing is 
differentially regulated in distinct brain regions, resulting in pDYN as well as mature peptides in axon 
terminals. Maturation is dependent on prohormone convertases PC1 and PC2. Processing of the 
mature peptides at the paired arginine residues yields Leu enkephalin from β-neoendorphin, DYN A 
and DYN B (Schwarzer C. 2009). 
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1.3.4.4  KOP receptor 
 
The kappa-opioid receptor is a G protein-coupled receptor (Fig. 19) and 
stimulation of the kappa-opioid receptor leads to the inhibition of adenylyl cyclase 
(Attali B. et al. 1989; Konkoy C.S., Childers S.R. 1989; Prather P.L. et al. 1995). 
The kappa-opioid receptor also plays a role in the regulation of calcium currents. The 
kappa-opioid receptor is coupled to an N-type calcium channel and stimulation of the 
kappa-opioid receptor inhibits calcium currents (Tallent M. et al. 1994). N-type 
calcium channels are expressed on presynaptic terminals and play a critical role in 
the release of neurotransmitters (Evans R.M., Zamponi G.W. 2006). 
Therefore, dynorphin-like peptides may inhibit the release of neurotransmitters by 
inhibiting N-type calcium channels. Furthermore, kappa-opioid receptor agonists 
have been shown to stimulate inwardly rectifying (i.e., ion conductance depends on 
membrane potential) potassium channels (Henry D.J. et al. 1995; Lewin B. et al. 
2007). The inward rectifying potassium current is a flow of potassium ions from the 
outside to the inside of the cell (Lu Z. 2004). The potassium conductance increases 
when the membrane potential becomes mor enegative and the potassium 
conductance decreases when the membrane depolarizes. The inward rectifying 
potassium channels play an important role in maintaining the resting potential of 
neurons (Lu Z. 2004). 
Pharmacological studies have provided some evidence for the existence of 
multiple kappa-opioid receptor subtypes, however, so far only one kappa-opioid 
receptor has been cloned  (Bruijnzeel A.W. 2009). The kappa-opioid receptor has 
been cloned from many species including rat, mouse, guinea pig, and human (Meng 
F. et al. 1993; Simonin F.et al. 1995; Xie G.X. et al. 1994; Yasuda K. et al. 1993; 
Zhu J. et al. 1995). Attali B. et al. (1982) described two types of kappa-opioid 
receptors in the spinal cord of guinea-pigs. Evidence has been provided for U-69593 
sensitive high-affinity binding sites (κ1) and U-69593 insensitive low affinity 
binding sites (κ2) (Zukin R.S. et al., 1988). High levels of kappa-opioid 
receptormRNA have been detected in the ventral tegmental area, substantia nigra, 
nucleus accumbens, caudate putamen, claustrum, endoperiform nucleus, various 
hypothalamic nuclei, and the amygdala of the rat brain (Meng F. et al. 1993). A 
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similar expression profile has been detected in the human brain (Simonin F. et al. 
1995; Zhu J. et al. 1995). 
 
 
 
 
 
 
Figure 19  3D structure of the KOP receptor complexed with the JDTic selective ligand. 
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1.3.4.5   Dynorphin and neuropathic pain 
 
Unlike the other two classes of known endogenous opioid peptides, the 
enkephalins and endorphins, intrathecal administration of dynorphin — whose N-
terminal sequence is identical to [Leu]enkephalin — does not elicit robust 
antinociception. Rather, dynorphin and those derivatives that lack the crucial N-
terminal tyrosine residue necessary for interaction with opioid receptors produce 
motor impairment and paralysis (Lay J. et al. 2001). Intrathecally administered 
dynorphin and its non-opioid derivatives produce hindlimb paralysis (Stevens C.W. et 
al. 1986; Faden A.I., Jacobs T.P. 1984) and enhanced sensitivity to sensory stimuli; 
at paralytic doses, these peptides are neurotoxic, depleting sensory neurons, motor 
neurons, and interneurons in the spinal cord (Long J.B. et al. 1988), and potentiating 
excitatory neurotransmitter release (Faden A.I. 1992; Skilling S.R. et al. 1992). At 
non-paralytic doses, dynorphin elicits long-lasting hyperresponsiveness to innocuous 
mechanical and noxious thermal stimuli (Vanderah T.W. et al. 1996; Laughlin T.M. 
et al. 1997). The essentially equivalent actions of dynorphin and its non-opioid 
derivatives strongly suggest that the effects of dynorphin are non-opioid. Increased 
responsiveness to innocuous and noxious sensory stimuli are reminiscent of signs of 
experimental and clinical neuropathic pain, suggesting that endogenous dynorphin is 
a key mediator of some aspects of neuropathic pain states (Lay J. et al. 2001). 
Peripheral nerve injuries are accompanied by an increase in spinal dynorphin 
(Draisci G. et al. 1991) especially in spinal interneurons (Botticelli L.J. et al. 1981). 
Within five days subsequent to nerve injury, dynorphin concentrations are elevated 
in the dorsal horn (i.e., where afferent axons terminate), peaking at day ten and 
persisting past day twenty post injury (Kajander K.C. et al. 1990); levels of mRNA 
for preprodynorphin correspondingly rise (Draisci G. et al. 1991). Complete nerve 
transection or nerve crush injury, however, produces only minimal changes in 
preprodynorphin mRNA levels (Draisci G. et al. 1991), suggesting that sustained 
afferent discharge is important for initiating the upregulation of spinal dynorphin. A 
study have indicated significant increases in spinal dynorphin-like content in the 
ipsilateral dorsal quadrant of the spinal cord after injury to the L5 and L6 spinal 
nerves (Malan T.P. et al. 2000). A bilateral increase in immunologically detected 
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dynorphin content is also observed in a sciatic cryoneurolysis model of neuropathic 
pain (Wagner R. et al. 1993). These studies suggest that the enhanced synthesis and 
release of spinal dynorphin after nerve injury may be common in chronic pain.  
In accordance with its classification as an endogenous opioid it has generally been 
concluded that elevated concentrations of spinal dynorphin function to dampen 
chronic nociceptive input after nerve injury (Draisci G. et al. 1991; Kajander K.C. et 
al. 1990). Nevertheless, considerable evidence reveals that dynorphin is actually 
pronociceptive in chronic pain states. For instance, the spinal administration of anti-
dynorphin antiserum reduces neurological impairment after nerve injury (Cox B.M. 
et al. 1985). Even the intrathecal injection of anti-dynorphin antiserum blocks the 
increased sensitivity to noxious thermal and innocuous mechanical stimuli that 
commonly accompanies injury to spinal nerves, but that the antiserum does not alter 
normal sensory thresholds in non-injured animals (Nichols M.L. et al. 1997). These 
findings support the hypothesis that the upregulation of spinal dynorphin is 
pronociceptive and important in the maintenance of the experimental neuropathic 
pain state (Lay J. et al. 2001). Further confirmation comes from experiments using 
prodynorphin knockout mice . These mice generally show normal responses to 
innocuous and noxious stimuli, thereby suggesting that basal levels of spinal 
dynorphin do not substantially participate in sensory thresholds. They also develop, 
as do their wild-type litter mates, neuropathic pain within two to three days after 
nerve injury, manifesting the typical increase in sensitivity to innocuous mechanical 
and noxious thermal stimuli. Unlike their wild-type litter mates, however, the 
prodynorphin knockout mice fail to sustain the neuropathic pain state for extended 
periods. By ten days after injury, the knockout mice are no more sensitive than they 
were prior to injury. In contrast, wild-type animals display neuropathic pain past day 
fourteen (Wang Z. et al. 2001). These data suggest that spinal dynorphin does not 
contribute to initial pain onset, but rather is critical for the maintenance of 
neuropathic pain (Lay J. et al. 2001). Correspondingly, early after nerve injury (ca 
two days), anti-dynorphin antiserum is ineffective blocking neuropathic pain while it 
becames effective ten days post injury, when spinal dynorphin levels are at their peak 
(Wang Z. et al. 2001). 
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1.3.4.6  Dynorphin and non-opioid systems 
 
Several investigators have demonstrated that dynorphin-induced neurological 
damage, such as hindlimb paralysis, loss of tail-flick reflex, and loss of neuronal cell 
bodies, can be prevented by antagonists and modulators of the NMDA receptor, 
which is known to be an important mediator of neuropathic pain states (Bakshi R., 
Faden A.I. 1990; Woolf C.J., Thompson S.W.N. 1991). Similarly, the long-lasting 
hyperresponsiveness to both innocuous and noxious stimuli that is elicited by 
intrathecal dynorphin is not blocked by the opioid receptor antagonist naloxone, but 
is prevented by pretreatment with the NMDA receptor antagonist (Vanderah T.W. et 
al.1996; Laughlin T.M. et al. 1997). 
The interaction of endogenous dynorphin and NMDA receptors in promoting 
neuropathic pain may be either direct or indirect. Studies conducted through 
displacement of highly-selective NMDA-channel radioligand, showed that 
Dynorphin is a positive allosteric modulator of the binding of the competitive 
NMDA receptor antagonist to the glutamate binding site (Dumont M., Lemaire S. 
1994). Thus, both direct and indirect binding analyses indicate that dynorphin A 
associates more strongly with NMDA receptors that  are in the closed channel state. 
shortening the mean open time and decreasing the probability of channel opening, 
but does not seem to affect single channel conductance.  Thus, although we cannot 
entirely rule out a direct, excitatory interaction between dynorphin and NMDA 
receptors, most evidence argues against direct interaction as a predominant 
mechanism for the excitatory actions of dynorphin, implying that non-opioid actions 
of dynorphin arise from interactions not involving NMDA receptors (Lay J. et al. 
2001). 
The hypothesis that the biological roles of dynorphin extend beyond opioid and 
NMDA receptors is supported by the finding that the application of dynorphin to the 
rat hippocampus results in a localized, dose dependent release of glutamate and 
aspartate (Faden A.I. 1992). Thus, dynorphin may indirectly potentiate NMDA 
receptor activity by enhancing the release of excitatory neurotransmitters, thereby 
resulting, for example, in hindlimb paralysis and neuronal cell loss (Lay J. et al. 
2001). It is feasible that dynorphin presynaptically promotes the release of these 
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neuropeptides by facilitating the rise in intracellular calcium concentration that 
would accompany activation of NMDA receptors. Indeed, neurotransmitter release 
depends on the transient increase in calcium that facilitates the interaction of proteins 
that mediate the docking and fusion of synaptic vesicles to the plasma membrane at 
the axon terminal (Catterall W.A. 1998). The novel mechanism of dynorphin-induced 
increase in [Ca2+]i is currently under investigation. Many potential calcium 
dependent mechanisms could facilitate neurotransmitter release by dynorphin (Fig. 
20). For example, NMDA receptor mediated currents are potentiated by protein 
kinase C and its activators (Chen L., Huang L.Y. 1992). In addition, many voltage-
gated calcium and potassium conductances are modulated by calcium through 
calmodulin, which also regulates the activity of a number of kinases that have been 
implicated in the regulation of neurotransmitter release (Llinas R. et al. 1991; 
Nichols R.A. et al. 1990) and in the phosphorylation of synaptic proteins (Nayak A.S. 
et al. 1996). A recent study of cultured embryonic spinal cord neurons shows that 
dynorphin A(1-13) stimulates an acute, transient increase in [Ca2+]i (Hauser K.F. et 
al. 1999). The excitatory effects of dynorphin are therefore apparent in both 
presynaptic (dorsal root ganglion) and postsynaptic (spinal cord) neurons. Prolonged 
exposure of these cells to dynorphin not only leads to an elevated basal level of 
[Ca2+]i, but also a significant loss of neurons; both of these effects are prevented by 
NMDA antagonists, suggesting that the neurotoxic effects of dynorphin are calcium 
dependent and mediated by NMDA receptors. These data support the notion that 
continuous exposure to dynorphin potentiates NMDA receptor activity, in accord 
with the neurotoxicity of intrathecal dynorphin to spinal cord neurons as mentioned 
above (Long J.B. et al. 1988).  
Concluding, under normal physiological conditions, spinal dynorphin plays a 
minimal role in the regulation of sensory thresholds, a conclusion that is supported 
by prodynorphin knockout mice (Wang Z. et al. 2001).  Rather, the opioid action of 
dynorphin is to suppress noxious inputs. However, under pathological conditions 
resulting from injury to peripheral nerves, the upregulation of spinal dynorphin 
accompanies the development of chronic pain states that can be blocked by anti-
dynorphin antiserum, suggesting that elevated spinal dynorphin is required for 
maintaining neuropathic pain (Fig. 20). The mechanisms that mediate the 
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upregulation of spinal dynorphin are unknown. Evidence from many laboratories 
consistently shows that neuronal excitation by dynorphin is mediated by an increase 
in intracellular calcium, which may act to enhance the release of transmitters from 
sensory primary afferent neurons or to potentiate NMDA receptor activity in spinal 
cord cells. The former possibility might represent a feedforward mechanism by 
which spinal dynorphin could maintain an elevated level of sensory excitation, 
whereas the potentiation of NMDA receptors would greatly facilitate the 
responsiveness of spinal thalamic neurons to excitatory input (Lay J. et al. 2001). 
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Figure 20 Possible mechanisms of dynorphin in maintaining neuropathic pain.  
Under normal conditions (left panel), dynorphin acts at opioid receptors (OR) to limit noxious input 
from a primary afferent: Specifically, dynorphin activates potassium efflux (through a G protein–
coupled inwardly rectifying potassium channel; GIRK) and inhibits calcium influx (through a voltage-
sensitive calcium channel; VSCC) in primary afferent and spinal thalamic neurons. Thus, excitatory 
neurotransmitter (glutamate) release is inhibited from the primary afferent terminal. After nerve injury 
(right panel), sustained input from the injured nerve drives the upregulation of spinal dynorphin 
through an unknown mechanism. The enhanced release of dynorphin stimulates the activity of 
molecules such as protein kinase C (PKC) and VSCC at the primary afferent to facilitate release of 
excitatory neurotransmitter and neuropeptides (e.g., substance P [SP] and CGRP). The binding site 
that mediates the effects of dynorphin is unknown. Enhanced neurotransmission potentiates the 
activity of postsynaptic glutamate receptors (AMPAR/KAIR) and NMDA receptors (NMDAR) by 
calcium/PKC dependent receptor phosphorylation. This is in part due to the activation of the 
substance P receptor (NK1R)/phospholipase C (PLC) pathway (Lay J. et al. 2001). 
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1.4 Brain-Derived Neurotrophic Factor 
 
Brain-derived neurotrophic factor (BDNF) is a 27-kDa polypeptide that 
belongs to the neurotrophin family binding with high-affinity protein kinase 
receptors (Trk), especially TrkB, and the unselective p75NGFR receptor. The BDNF 
gene has a complex structure with multiple regulatory elements and four promoters 
that are differentially expressed in central or peripheral tissue (Tapia-Arancibia L. et 
al. 2004). It is well known to play an important role in the survival, differentiation, 
and outgrowth of select peripheral and central neurons during development and in 
adulthood (McAllister A.K. et al. 1999; Sohrabji F., Lewis D.K. 2006). 
BDNF supports the survival and maintenance of sensory neurons, retinal 
ganglia, certain cholinergic neurons, spinal motor neurons and some dopaminergic 
neurons. In the brain, the synthesis of BDNF, as investigated in the hippocampus and 
cortex, is affected by neuronal activity and has a unique role in synaptic plasticity. 
The use or disuse of synaptic pathways results in strengthening or weakening of 
connections between neurons, resulting in increased or decreased formation of 
synapses at axon collaterals and dendritic spines (Allen S.J. et al. 2013). The BDNF 
gene is one of the most tightly regulated genes, with 11 exons and 9 functional 
promoters (Pruunsild P. et al 2007) and gives rise to approximately 34 transcripts 
(Gabriele B., TongiorgiE. 2009) in response to various stimuli. Importantly, whereas 
the other neurotrophins are released via the constitutive pathway, BDNF can also be 
secreted via an activity-dependent regulated secretory pathway in neuronal cells. 
Processing by proBDNF or proNGF to themature form may occur inside or outside 
the cell. Intracellular processing is via furin; extracellular processing occurs via 
plasmin, generated following the activation of plasminogen by tissue plasminogen 
activator (tPA), which is co-released with proBDNF (Pang P.T. et al. 2004). During 
regulated secretion, BDNF (the mature domain) associates with a sorting receptor 
carboxypeptidase E (CPE), whilst the pro domain binds the sortilin receptor 
ectodomain (Zhang C.F. et al. 1999). ProBDNF also associates with the huntingtin-
associated protein-1 (HAP1); sortilin stabilises the complex of proBDNF and HAP1, 
thus reducing proBDNF degradation. This also assists in the intracellular cleavage of 
proBDNF by furin to produce mature BDNF, and release by the secretory pathway 
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(Yang M. et al. 2011). A common polymorphism (proBDNFVal66Met) precludes the 
binding of proBDNF to sortilin which is thus not able to undergo regulated secretion. 
There are a number of consequences to this, one of which may be impairment of 
memory function (Egan M.F. et al. 2003). 
 
 
1.4.1 Trk receptors 
 
The Trk family of receptors includes TrkA, TrkB and TrkC which are 
instrumental in carrying out the cellular effects of neurotrophins. P75NTR, a member 
of the tumour necrosis receptor superfamily exhibits some structural similarities to 
Trk family of receptors and interacts with members of the Trk family including TrkB 
receptor and influences its signalling. The Trk receptors are a major class of 
neurotrophin receptors, as they promote cell survival and inhibit apoptosis in the 
specific populations of CNS neurons. Trk receptor signaling is activated in response 
to neurotrophin binding; each neurotrophin has high affinity for a particular receptor, 
Nerve Growth Factor (NGF) binds to TrkA, Brain-Derived Neurotrophic Factor 
(BDNF) and NT-4/5 bind to TrkB and NT-3 binds TrkC (Skaper S.D. 2012). (Fig. 
21) 
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Figure 21 Neurotrophins and their receptors.  
Neurotrophins are synthesized then processed by protease cleavage to generate the mature, processed 
ligands. All the unprocessed neurotrophins bind with high affinity to the p75NTR; the processed 
isoforms also bind to p75NTR, albeit with lower affinity. The processed ligands bind to the Trk 
receptors, NGF binds TrkA and BDNF, NT4 binds TrkB, and NT3 preferentially binds to TrkC but 
can activate all the Trks (Segal R.A. 2003).  
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The three Trk receptors exist as monomers and their dimerization is induced by the 
binding of their respective dimeric neurotrophins (Fig. 22). Specifically, BDNF 
associates with the extracellular domain of TrkB by interacting with the third leucine 
rich motif, the cysteine cluster-2 domain and the immunoglobin-2 domain, thereby 
stimulating receptor dimerization. Upon BDNF binding, TrkB receptor is 
autophosphorylated in the activation loop, of its cytoplasmic tyrosine kinase domain, 
at Tyr702, 706 and 707 (TrkA-Tyr670, 674 and 675), which enhances subsequent 
phosphorylation at two additional residues, which will act as docking sites for 
downstream effectors. Phosphorylation of TrkB-Tyr516 (or TrkA Tyr490) induces 
an interaction between the receptor and the PTB domain of Shc, which initiates Ras-
MAPK and PI3K signaling pathways and subsequently, activates Akt1/PKB. 
Similarly, phosphorylation of TrkB-Tyr817 (or TrkA Tyr785) facilitates association 
between the receptor and PLCγ1, which stimulates the release of Ca2+ and 
upregulates PKCδ (Hubbard S.R. 2007). 
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Figure 22  The binding of neurotrophins produces dimerization of each receptor. 
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1.4.2 BDNF and neuropathic pain 
 
In experimental animals, peripheral nerve damage, such as that generated by 
chronic constriction injury (CCI) of the sciatic nerve, induces pain-related behaviours 
that are accepted as a model for human neuropathic pain. Seven or more days of CCI 
promotes release of cytokines, chemokines and neurotrophins at the site of nerve 
injury. These interact with first order primary afferent neurons to produce an 
enduring increase in their excitability. The central terminals of these damaged 
afferents exhibit spontaneous activity and release additional cytokines, chemokines, 
neuropeptides, as well as ATP and brain derived neurotrophic factor (BDNF) into the 
dorsal horn. These exert long term effects on dorsal horn excitability and/or alter the 
state of activation of spinal microglial cells. Microglia stimulated in this way release 
of a further set of mediators, again including BDNF, that promote a slowly 
developing increase in excitability of second order sensory neurons in the dorsal horn 
of the spinal cord (Fig. 23). This ‘central sensitization’ which develops progressively 
during CCI, is responsible for the allodynia, hyperalgesia and causalgia that 
characterize human neuropathic pain (Biggs J.E. et al 2010). 
In CCI model, NGF is produced abundantly around degenerating Ab and Ad fibers 
by Schwann cells and macrophages. This NGF is retrogradely transported by intact C 
fibers to the DRG, leading to an increased production of BDNF in small-to-medium 
neurons. Corroborating the hypothesis of changed target-derived NGF as cause of 
altered BDNF expression, Obata K. et al. 2004 administered recombinant NGF 
intrathecally (i.t.) in Sprague–Dawley rats and found an increased BDNF expression 
in small and medium DRG neurons. An increasing number of studies indicate that 
pain is not solely mediated by neurons but that glial cells and astrocytes have an 
active role in the initiation and maintenance of neuropathic pain. A way in which 
microglia may contribute to neuropathic pain is through the activation of their P2X4 
receptor by ATP. This leads to an influx of extracellular calcium and subsequent 
activation of p38 MAPK resulting in an increased synthesis and release of BDNF 
through soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
dependent exocytosis (Vanelderen P. et al. 2010). 
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Whereas microglial activation triggers pain onset, enduring activation of 
astrocytes is thought to be responsible for the maintenance of central sensitization. 
Changes in thalamic and cortical physiology, long-term sensitization of peripheral 
nociceptors and changes in descending inhibition from the rostral ventromedial 
medulla and periaqueductal grey and are also involved. 
Despite the documented importance of interleukin 1β (IL-1β) and tumor 
necrosis factor a (TNF-α), MCP-1/CCL-2, ATP, BDNF and fractalkine in central 
sensitization, findings to be reviewed below point to the possibility that BDNF is 
alone capable of bringing about one critical step; the interaction between activated 
microglia and neurons. It may therefore serve as a final common path for a 
convergence of perturbations that culminate in the generation of neuropathic pain 
(Fig. 23). Several lines of evidence are consistent with the central role for BDNF in 
the initiation of central sensitization. BDNF released by ATP stimulated microglia 
causes a depolarising shift in the anion reversal potential of lamina I neurons by 
ways of a reduction in the expression of the potassium-chloride exporter KCC2. The 
resultant perturbation of the chloride gradient leads to attenuation of the inhibitory 
actions of GABA/glycine. In some neurons, the chloride gradient may actually 
reverse so that inhibition is converted to excitation (Biggs J.E. et al 2010, Coull J.A. 
et al. 2005). 
Another possible mechanism by which BDNF induces central hypersensitivity is by 
enhancing NMDA receptor-mediated responses in the DH: the ventral root potential 
is routinely used as an indirect but accurate measure of spinal excitability. NMDA 
evoked ventral root depolarization amplitudes increased significantly after BDNF 
superinfusion in isolated hemisected spinal cords (Vanelderen P. et al. 2010). All 
these observations suggest a pro-nociceptive effect of BDNF, at least at the level of 
the spinal cord. Although it has been reported that viral vector-driven expression of 
BDNF and grafting BDNF-expressing cells into the spinal cord reduces signs of pain 
associated with CCI this may reflect analgesic actions within the midbrain. 
These and other observations raise the possibility that BDNF is alone capable of 
conveying many aspects of the communication between activated microglia and 
neurons during the onset of central sensitization. This appears to occur despite the 
presence and potential participation of mediators such as IL-1β, TNF-α, fractalkine, 
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chemotaxic cytokine ligand 2 also known as monocyte chemoattractant protein 1 
(CCL-2/MCP-1). These may exert their actions at other points in the central 
sensitization process (Fig. 23) or perhaps function in a parallel fashion to BDNF in 
microglial - neuron interactions (Biggs J.E. et al 2010). 
 
  
 
Figure 23 Scheme to show interactions between primary afferents, dorsal horn neurons 
microglia and astrocytes in the context of chronic pain.  
Literature citations supporting the illustrated interactions include; IL-1β, MCP-1/CCL-2 and TNF-a in 
acute and chronic excitation of primary afferents; MCP-1/CCL-2, ATP, BDNF and fractalkine in 
microglial activation; autocrine actions of TNF-α in microglia; IL-1β release from microglia and its 
actions on neurons; BDNF release from microglia and its actions on neurons; role of MCP-1/CCL-2 in 
astrocyte-neuron interactions, actions of TNF-α on astrocytes and neurons. To the best of our 
knowledge actions of IL-1β on astrocytes in spinal cord has not been demonstated but there is 
evidence for this interaction in other neuronal systems (Biggs J.E. et al 2010). 
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1.5 Epigenetics 
 
 
1.5.1 General consideration 
 
Epigenetics (from the Greek, epi-: επί- over, above; and -genetics) correspond 
to the study of heritable changes in gene expression or in the cellular phenotype 
caused by mechanisms other than changes in the DNA sequence (Feinberg A.P., 
Tycko B. 2004). Cellular differentiation is a well know example of relevance of 
epigenetic mechanism. If all cells within an organism have the same DNA (Nestler 
E.J 2009) then the ability to have different cells with different functions must be due 
to a selective activation or silencing of particular genes within genome (Grewal S.I., 
Moazed D. 2003). Actually, it has been demonstrated that epigenetic events, 
altogether with genetic events, plays a crucial role in tumor progression (Jordà M., 
Peinado M.A. 2010). 
Three epigenetic mechanisms are considered the most important ones: genomic 
imprinting, histone modifications and DNA Methylation (Feinberg A.P., Tycko B. 
2004) (Fig. 24). Genomic Imprinting refers to the relative silencing of one parental 
allele compared with the other parental allele as consequence of differentially 
methylated regions within or near imprinted genes. 
Histone modifications, principally acetylation, methylation and phosphorylation, are 
important in transcriptional regulation due the ability to induce chromatin structure 
modification, altering DNA accessibility (Feinberg A.P., Tycko B. 2004). DNA 
methylation is the most common epigenetic mechanism (Jordà M., Peinado M.A. 
2010) and consists in a covalent modification of DNA, in which a methyl group is 
transferred from S-adenosylmethionine to the C-5 position of cytosine by a family of 
cytosine (DNA-5)-methyltransferases (Feinberg A.P., Tycko B. 2004) and occurs 
predominantly in the cytosines that precede guanines (CpG) (Bird A.P. 1986) (Fig. 
25). 
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Figure 24. Schematic Representation of Epigenetic Processes and General Chromatin 
Structure 
(A) DNA methylation. (B) Histone variants and modifications. (C) Chromatin remodeling complexes. 
(D) Nucleosomes. 
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1.5.2 Histone modifications 
 
Gene expression can also be modulated by the chromatin state. DNA is packed in the 
nucleus of eukaryotic cells through its chromatin organization. The nucleosome, the 
fundamental unit of chromatin structure, consists of 146 base pairs of DNA 
wrappped around an octamer of histone made up of two copies of each of the core 
histone (H2A, H2B, H3 and H4) (Kouzarides T. 2007) (Fig. 25). 
 
 
 
Figure 25. DNA wrapped around histone octamers to form nucleosomes 
 
 
Each core histone is composed of a structured domain and an unstructured amino-
terminal tail of varying lengths from 16 amino acid residues for H2A, 32 for H2B, 44 
for H3 and 26 for H4, protruding outward from the nucleosome (Taniura H. et al. 
2007). These proteins provide not only a solid structure; N-terminal regions of 
histones which protrude from the nucleosome are susceptible to interactions with 
other proteins. Chromatin can exist either in a decondensated, active arrangement, 
termed euchromatin, or in a condensated, inactive state, i.e. heterochromatin. 
The post-translational modification of the residues at histone tails are: methylation of 
lysines and arginines, acetylation, phosphorylation, ubiquitination, sumoylation, and 
ADP-ribosylation. Two widely studied histone modifications are histone acetylation 
and phosphorylation. 
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Histone acetylation is linked with transcriptional activation, while deacetylation is 
related to transcriptional repression (Berger S.L. 2007).  
Histone acetylation is a reversible modification of lysine residues within the amino-
terminal tail domain of core histone; histone acetyltransferase (HATs) transfers an 
acetyl-group from acetylcoenzyme A to the ε-amino group of the lysine residue, 
while histone deacetylase (HDACs) acts in the reverse to remove the acetyl group. 
Also histone can be methylated by histone methyltransferases, inducing changes in 
the chromatin structure. 
Methylation may create binding sites for other regulatory proteins thus influencing 
the chromatin structure, either condensating or relaxing the structure (Chouliaras L. 
et al.  2010). 
Although DNA methylation and histone modifications can act independently, they 
can also interact with each other. DNA methylation is associated with histone 
modifications through methyl CpG binding proteins interaction with dynamic 
complexes containing histone-modifying enzymes that promote gene repression and 
DNA replication and repair (Klose J., Bird A.P. 2006).  
The binding of some deoxy-methylcytosine binding proteins to methylated sequences 
attracts complexes containing co-repressors and histone deacetylases, leading to a 
change in the chromatin structure from an open, trancriptionally active form to a 
more compact, inactive form, inaccessible to the transcription machinery 
(Richardson B. 2003). 
 
 
1.5.3 DNA Methylation 
 
DNA methylation appears to be one of the most important epigenetic mechanisms 
used by the cell, for the establishment and manteinance of the correct patterns of 
gene expression (Egger G. et al. 2004).  
DNA methylation patterns are stablished during differentiation, and serve to suppress 
genes unnecessary for the function of the mature cell. DNA methylation in mammals 
occurs in the cytosin of the CpG dinucleotide via a reaction catalysed by enzymes 
named DNA methyltransferases (DNMTs) and the recognition of methylated 
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cytosines is done by proteins that posses a specific binding domain, the so-called 
methyl-CpG binding domain. DNMTs are expressed throughout neural development, 
and in the adult brain in selective regional and cell-specific patterns including mature 
stem cell generative zones mediating ongoing neurogenesis (Feng J. et al. 2007).  
Moreover, DNMTs are actively regulated by physiological and pathological states 
and interactions, and they promote neuronal survival, plasticity and stress responses 
(Ooi S.K. et al, 2007).  
The methylation of CG sequences can affect nearby gene expression. 
Hypomethylation of regulatory sequences usually correlates with gene expression, 
while methylation results in transcriptional suppressor. In general, the more CpG 
islands located in the promoter of a gene, the more the trancription level is dependent 
on DNA methylation (Graff J. Mansuy I.M. 2008).  
Methylation of CpG units disrupts the binding of transcription factors and attracts 
proteins known as methyl-CpG binding domain proteins that are associated with 
gene silencing and chromatin compaction (Antequera F., Bird A. 1993). 
The CpG islands, regions with more than 500 bp and a G + C content larger than 
55%, are localized in the promoter regions of 40% of all the genes in mammals and 
are normaly maintaind in the non-methylated form (Bird A.P., Wolffe A.P. 1999), but 
the CpGs located outside the CpG islands are usually methylated (Urdinguio R.G. et 
al, 2009). 
The importance of DNA methylation in the function of normal cells is evidenced by 
its role in differentiation, X chromosome inactivation, genomic imprinting 
maintenance of chromatine structure, and suppression of "parasitic" DNA.  
It has been observed that multiple exogenous agents can affect DNA methylation, 
and it is possible that transient exposure to a DNA methylation inhibitor can have 
long term effects on DNA methylation.  
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1.5.4 Epigenetc and Pain 
 
Evidence suggests that more than 1,000 genes in spinal dorsal horn neurons are 
epigenetically regulated within the first minutes to hours following a peripheral nerve 
injury (Price D.D. et al. 2006; Tajerian M. et al. 2011; McCall C.E. et al. 2011). 
Often, these early modifications are followed by more sustained epigenetic processes 
shaping synaptic connectivity and formation of pathologic long-term pain. 
Several critical “first responder” transcription factors, including NF-kB (nuclear 
factor k light-chain-enhancer of activated B cells), c-Jun, c-Fos, and several hormone 
activated receptor proteins, serve as drivers for wide-ranging epigenetic responses to 
cellular stress. Present but inactive in many vascular, nerve, and immune cells, these 
transcription factors become activated in response to cell insult and are able to 
rapidly access chromosomal DNA as demethylation unspools chromatin structure to 
initiate production of a reparative cascade of inflammatory cytokines including TNF-
α as well as T-cell and Bcell regulating interleukins. The nearly simultaneous 
dynamic remodeling of chromatin through the addition of methyl groups toDNA and 
the removal of acetyl groups from histone proteins regulates production of immune 
suppressing glucocorticoids, providing a critical check and balance to overactivation 
of immune responses. Epigenetic changes to chromatin structure are similarly linked 
to suppression of pain inhibiting GABA synthesis, changes in expression patterns of 
sodium and potassium channels driving afferent input into the spinal cord, and 
activity-dependent upregulation of pronociceptive brain-derived neurotrophin factor 
(BDNF) in the spinal cord, as well as functional regulation of mu opioid receptors, 
the principle receptor for endogenous endorphins, encephalin and as well as opioid 
analgesics. 
Sustained DNA methylation downstream from early effector transcription factors, for 
example, has been linked to an accelerated degeneration of vertebral disks in low-
back pain in both animal models and human subjects. Sustained histone 
deacetylation has been identified as a factor driving long-lived C-fiber dysfunction, 
decreased responsiveness to morphine analgesia, and an upregulation of 
pronociceptive metabotropic glutamine receptors in animal nerve injury models. 
Epigenetics processes also provide a mechanistic understanding of the phenomenon 
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of opioid-induced hyperalgesia, with chronic opioid use reported to stimulate DNA 
methylation leading to upregulation of µ-opioid receptors and increased pain with 
continued opioid use (Lessans S., Dorsey G. 2013). 
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2. AIM OF RESEARCH 
 
The research project conducted during these years, is focused on the neuroplastic 
alterations occurring in chronic pain conditions. 
Within this context, our attention has focused on the study of pathophysiological 
phenomena associated with nerve-injured neuropathic pain. 
Chronic pain is an enormous medical-health problem, it is associated with a 
significantly reduced quality of life and a higher risk of depression and other mental 
health disorders. It was estimated that approximately 20% of the adult population 
have chronic pain, and separate to the physical and emotional burden it brings, the 
financial cost to society is huge, currently estimated at over €200 billion per annum 
in Europe, and $150 billion per annum in the USA (Tracey I., Bushnell M.C. 2009). 
Treatment options are limited with many patients either not responding or having 
incomplete pain reduction. 
Neuropathic pain is not a single entity; it is a heterogeneous group of conditions that 
differs not only in aetiology but also in location and symptoms do neither respect 
cause nor anatomical site. Diabetes, immune deficiencies, malignant diseases, 
traumatic and ischemic disorders may all give rise to neuropathic pain. The 
anatomical sites of lesions causing neuropathic pain are multiple: they can be located 
from the peripheral receptor to the highest cortical centers. The most common 
locations are the peripheral nerves, the plexus, dorsal nerve roots, the spinal cord and 
the brain. In spite of the diverse aetiology and topography, the clinical picture is in 
many cases surprisingly similar suggesting that pain in these many disorders share 
common mechanisms. Different studies have shown that a cascade of temporally 
related biological changes follow damage to the nervous system, which eventually 
results in a sensitization of neural elements involved in the processing of noxious 
information (Costigan M., Woolf C.J. 2000; Woolf C.J., Salter M.W. 2000.). 
Therefore pain is an expression of maladaptive plasticity within the nociceptive 
system, a series of structural and functional changes that constitute a neural disease 
state (Costigan M. et al. 2009). Although the significance of these molecular changes 
following nerve damage still are under exploration, they may represent a link that 
ties different neuropathic conditions together (Jensen T.S. et al. 2001). Hence, an 
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understanding of the dynamic events after nerve damage may be a key to understand 
hyperexcitability and to move treatments from merely suppressing symptoms to a 
disease modifying strategy aimed at preventing this maladaptive plasticity. 
Animal models provide pivotal systems for preclinical studies of neuropathic pain 
and serve as an experimental basis for mechanistic investigations and testing new 
therapeutic interventions. Over time, various tests and models were developed in 
rodents to provide tools for fundamental and translational research on the topic. 
The ideal models should result in reproducible sensory deficits such as allodynia, 
hyperalgesia and over a sustained period. Animal research must always be evaluated 
by three general criteria: the generation of knowledge, the ability of the study to be 
reproduced, the relevance of the study and the predictive validity of clinical pain 
states. One of the most widely used experimental models, which more closely 
resembles behavior of peripheral neuropathy in rodents, is the chronic constriction 
injury to the sciatic nerve (CCI). It is reliable and easily reproducible model, able to 
induce hyperalgesia and allodynia (Colleoni M., Sacerdote P. 2010). 
Through the use of this model it is possible to study molecular changes of different 
endogenous systems widely recognized to be involved in nociception. 
The endogenous opioid system is probably the most important system involved in 
control of nociceptive transmission and it is therefore an important target of 
investigation in pain research. In this context, the neuropeptide dynorphin, though 
representing the endogenous ligand of the κ opioid receptor (Chavkin C. et al. 1982), 
has been also suggested as a key mediator of some aspects of chronic/neuropathic 
pain by numerous studies (Lai J. et al. 2001). 
Beside these system, an important role for certain neurotransmitters / 
neuromodulators such as BDNF has also been recently suggested. In fact, its 
involvement in the peripheral and central sensitization phenomena is known. At this 
regard, its involvement in the disinhibition caused by an alteration of the Cl- cell 
gradient followed by the inversion of GABAergic inhibitory activity (Kohno T. et al. 
2005) and by an increase in the NMDA receptors-mediated excitatory activity 
(Vanelderen P. et al. 2010) has been already reported in the Introduction.   
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Moreover, a possible link between BDNF and dynorphin has been recently proposed 
with a role of a downstream effector played by dynorphin in some actions involving 
BDNF (Logrip M.L. et al. 2008). 
Beside the classical opioid receptors, a new GPCR receptor, initially called ORL-1 
(opioid receptor like 1) and now known as NOP, has been identified, followed by the 
identification of its endogenous ligand: the neuropeptide nociceptin. This 
endogenous system, although structurally very similar to the classical opioid system, 
represent an independent system. It is well established that the nociceptin and all 
exogenous NOP receptor ligands have pronociceptive and antinociceptive effects 
depending on the drug dose and site of administration. If administered at a 
supraspinal level, the nociceptin induces hyperalgesia. Intrathecal and peripheral 
administrations cause hyperalgesia at low doses and analgesia at high doses (Mika J. 
et al. 2010). 
Based on these evidences, the primary aim was to evaluate the effects on gene 
expression of precursors of opioid peptides and receptors (ppN/OFQ, pDYN, pENK, 
pNOP) and pBDNF at spinal level (SC and DRGs) at different intervals after nerve 
injury and to understand the physiological function of these systems in the 
development of neuropathic pain. 
Based on results derived from studies at spinal levels and even more on the growing 
importance conferred on the cerebral neuroplastic alterations we investigated in the 
same experimental conditions gene expression changes at supraspinal level, focusing 
our attention on N/OFQ-NOPr system, DYN-KOPr system and BDNF. 
Recently, an increasing number of experimental evidence suggest that changes in 
gene expression induced by pain condition may be mediated by epigenetic 
mechanisms (McMahon S.B., Denk F. 2012). There are two types of chromatin 
modifications involved in the regulation of gene transcription: histone modifications 
and DNA methylation. Increasing evidences on the relationships between changes in 
methylation of lysine on histone 3, and alteration of gene expression are evident 
(Boggs B.A. et al. 2002). 
Epigenetic mechanisms seem to play a role in neurol plasticity resulting from chronic 
pain (Chwang W.B. et al. 2007; Koshibu K. et al. 2009; Lubin F.D. et al. 2008). 
  
 
87 
 
With this purpose, studies have been performed using epigenetic Chromatin Immuno 
Precipitation assays (ChIP) in order to observe different changes in the promoter 
regions of DYN and BDNF genes, related to the alterations in gene expression, 
observed at spinal level.  
We also investigated BDNF involvement in neuropathic pain through the analysis of 
the behavioral signs of hyperalgesia and allodynia in a strain of mice partially 
lacking for BDNF, subjected to CCI. 
The interest on the N/OFQ-NOPr system has been further analyzed, in the constant 
experimental context, evaluating if levels of bioactive N/OFQ peptide could be 
related to gene expression changes observed in the same cerebral areas. 
Simirarly, in the last part of the present study, in order to provide a unique approach 
to explore receptor localization and function in vivo of the N/OFQ-NOPr system, I 
focused my study on the characterization and validation of an innovative knock-in 
mouse strain. This model can be useful for a better characterization of 
pathophysiological role of this system in neuropathic pain. 
In 2005, Kieffer and colleagues produced the first transgenic mice containing a 
GPCR, the δ opioid receptor, with enhanced Green Fluorescent Protein (EGFP)  
fused on the C-terminal (Scherrer G. et al. 2006). According to this strategy the 
fusion of EGFP to NOP receptors could provide a unique technology useful to 
answer different questions concerning the involvement of N/OFQ-NOPr system in 
chronic pain condition. NOP-EGFP mice will allow the visualization of  receptors in 
the brain, spinal cord and DRGs. In addition, this murine model will permit to 
quantify changes in NOP receptor levels caused by different experimental conditions, 
such as neuropathic pain, either in basal condition or after different pharmacological 
treatments. 
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3. MATERIALS AND METHODS 
 
3.1  Animals 
 
All animal experiments were carried out in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and National 
(Ministry of Health) laws and policies (authorization no. 204/2008-B). Care was 
taken to minimize the number of experimental animals and to take measures to 
minimize their suffering. 
Adult male Swiss mice (ICR/CD-1, Harlan Lab., Udine, Italy) or BDNF +/- 
and BDNF +/+ (provided by Dr Marco Canossa, University of Bologna) weighing 
20–30 g at the beginning of the experiment were housed five per cage in standard 
Macrolon cages (Tecniplast Gazzada, Buguggiate, Italy) in a temperature- and 
humidity-controlled room with a constant 12-hour light/dark cycle (lights on at 7am). 
The mice were allowed to acclimatize for at least 1 week before the start of the 
experiments, during this time the mice were handled daily. Free access to standard 
lab chow and tap water were available ad libitum, except during behavioral 
experiments. 
NOP-eGFP knock-in mice, obtained from Dr. Brigitte Kieffer (Institut de 
Génétique et de Biologie Moléculaire et Cellulaire, Ilkirch, France), were bred inthe 
Neuropharmacology Laboratory, directed by Dr. Lawrence Toll, at Torrey Pines 
Institute for Molecular Studies, Port St. Lucie, Fl, USA. 
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3.1.1 Transgenic BDNF mice 
 
In the gene-targeting construct, a 560-bp fragment from the BDNF protein-
coding exon was replaced by the selection marker-a neomycin-resistance gene 
flanked by a glycerate kinase gene promoter and a polyadenylylation signal-thus 
deleting most of the mature BDNF coding sequence (Fig. 26). Homozygous BDNF -
/- mutant mice were retarded in growth and had reduced weight (down to only 25% 
of the wild type) from postnatal day 3 (P3) on. They displayed aberrant limb 
coordination and balance, showed a loss of neurons in the dorsal root ganglia, and 
usually died between 2 and 4 weeks after birth. Such abnormalities were never 
observed in heterozygous BDNF +/ - mice (Korte M. et al. 1995). 
 
 
                  
 
Figure 26 Production of BDNF-deficient mice. 
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3.1.2   NOP-EGFP mice 
 
Knock-in mice were constructed so that the NOP receptor with eGFP fused at 
the C-terminus is expressed in place of the native receptor with eGFP attached to the 
C-terminal of NOP receptors.  The mice grow and breed normally.   
 
3.1.2.1   Genotyping.  
 
Total DNA was isolated from the mouse tail using DNeasy Kit (Qiagen).  
The NOP primers were: 
 5′-CCCTGCACCGGGAGATGCA-3′ (forward) 
 5′-GACAGAGGCCATGGAGGCC-3′ (reverse),  
producing a 319 bp PCR product to amplify wild type NOP DNA.  
The NOP-eGFP primers were: 
5′-CCCTGCACCGGGAGATGCA-3′ (forward) 
5′-GCGGACTGGGTGCTCAGGTA-3′ (reverse),  
producing a 733 bp PCR product to amplify the NOP-eGFP transgenic DNA. PCR 
will be performed with an annealing temperature of 60°C using the GoTaq 
FlexiDNA kit (Promega). Fig.27 
 
 
Figure 27  NOP-EGFP knockin mice. Targeting strategy and genotyping PCR products.  
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3.2   Surgical procedures 
 
Mice were subjected to a right sciatic nerve lesion, according to the chronic 
constriction injury (CCI) model (Bennet G.J, Xie Y.K.  1986), adapted to the mouse. 
Briefly, mice were anesthetized with  (equitesina:Na-penthobarbital and chloral 
hydrate mixture; 30 mg/kg i.p.) and the lower back and right thigh were shaved. The 
shaved area was then cleansed with 70% ethyl alcohol. A linear skin incision was 
made along the lateral surface of the biceps femoris and blunt forceps were inserted 
into the muscle belly to split the muscle fibers and expose the sciatic nerve. The tips 
of the forceps were passed gently under the sciatic nerve and lifted to pass three 4-0 
silk sutures under the nerve, 1mmapart. The sutures were then tied loosely around the 
nerve and knotted twice to prevent slippage. The incision was cleansed and the skin 
was closet. The mice were then placed on a warmed surface and following recovery, 
were returned to their home cages and checked routinely for 72 h. A separate control 
group of sham operated mice underwent the same surgical procedure with the 
exception of the ligation of the sciatic nerve. 
 
 
3.3  Behavioral tests 
 
The presence and development of behavioural signs of neuropathic pain were 
assessed by the Hargreaves’ plantar test (hyperalgesia) (Hargreaves K. et al. 1988) 
and the cold acetone test or cold plate test (allodynia), performed at different 
intervals, three seven and fourtheen days, after the sciatic nerve lesion. 
 
 
3.3.1   Plantar test 
 
Paw withdrawal latencies to heat were measured according to the method of 
Hargreaves applying a standard Ugo Basile Algesiometer (Comerio, Italy). Animals 
were placed in the examination room 10 min prior to testing to allow acclimation to 
the light and testing environment. After 5 min, animals were placed in Plexiglas 
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enclosures with glass floors and a radiant heat source was positioned under one hind 
paw (Fig. 27). The intensity of the beam (30 A.I.) was selected to produce an average 
baseline threshold of approximately 10 s. A 30–second cut-off was employed to 
prevent tissue damage in non-responsive subjects. 
The time to paw withdrawal was recorded automatically. Each hind paw was tested 
three times. 
 
 
 
 
 
 
 
Figure 28  Plantar Test (Hargreaves's Apparatus); Ugo Basile 
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3.3.2   Acetone test 
 
The acetone test was used to investigate paw response to cold. Mice were 
placed in plexiglass cages on a wire mesh. The plantar surface of the hind paw was 
touched with a drop (40 µl) of acetone and the reaction of the mouse was recoded, by 
assigning a score as shown in Tab. 4. The cut off time for the registration of the score 
was 30 seconds. Each hind paw was tested three times at 5-minute intervals to avoid 
sensitization (Caspani O. et al. 2009). 
 
   
Score  Behavior  
0  No response  
0,5  Licking response  
1  Flinching and brushing of the paw  
2  Strong flinching  
3  Strong flinching and licking  
     
 
Table 4 Score Assignement Acetone test. 
 
 
 
3.3.3   Cold-Plate test 
 
Thermal allodynia to cold stimulus was assessed by using the hot/cold-plate 
analgesia meter (Bennett G.J, Xie Y.K. 1988) (Fig. 28), as previously described 
(Ruiz-Medina J. et al. 2011). Briefly, mice were placed into compartment enclosures 
on the cold surface of the plate which is maintained at a temperature of 5 ± 0.5°C. 
Each animal was placed on the cold plate, and the time at which it showed a 
response, such as elevation of hindpaw, was recorded. 
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Figure 29 Cold Plate Test. 
 
 
 
 
 
3.4   Tissue collection 
 
Seven and Fourteen days after CCI, ICR-CD1 or BDNF +/- animals were 
sacrificed and the following areas were collected:  the L4, L5 and L6 dorsal root 
ganglia (DRGs), the L4-L6 segment of the spinal cord (SC), the brainstem (BS), 
thalamus (Th), amygdale (Amy), hypothalamus (Hyp), hippocampus (Hippo), 
caudate-putamen (CP), nucleus accumbens (Nac) as well as the somatosensory 
(SSCx), prefrontal (PFCx), and anterior cingulate cortices (ACCx) and stored at  a -
80° C until use. 
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3.5 Real-Time quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) 
  
  
3.5.1 Extraction of total RNA 
  
Total RNA was prepared according to the method previously described 
(Chomczynski P., Sacchi N. 1987). The RNA was extracted from single tissue 
samples by homogenizing with TRI Reagent solution (Ambion Inc. Italy), containing 
phenol and guanidine thiocyanate (Ambion), 1 mL TRI Reagent solution per 50-100 
mg tissue. Then, 0.2 ml chloroform/2 ml of homogenate, and centrifuging the 
suspension at 12,000 x g for 10-15 minute at 4°C, and was transfered the aqueous 
phase to a fresh tube. A volume of 0.5 ml isopropanol was added, incubated for 15 
min at 4°C and the RNA pellet was isolated by centrifugation at 12,000 x g for 25 
min at 4°C.  
The pellet was washed twice with 75% ethanol, dried under vacuum and then 
resuspended in 25 µl of Rnase-free water. Total RNA, digested with DNase RNase-
free enzyme to eliminate genomic DNA content, was quantified by measurement of 
absorbance at 260 nm (1OD/ml = 40 µg RNA/ml). The ratio OD260/OD280 > 2 
provided an estimate of the purity of the total RNA. 
The quality of total RNA was evaluated by 1% agarose gel.  
 
3.5.2 Reverse Transcription and PCR 
  
RNA samples were subjected to DNase treatment and converted to cDNA 
with the GeneAmp RNA PCR kit (Applied Biosystems, Foster City, CA, USA) by 
using random hexamers (0.45 µg of total RNA in a final reaction volume of 20 µl). 
The cDNAs were subsequently diluted three times.  
Relative abundance of each mRNA species was assessed by real-time RT-PCR 
employing 2 µl of the diluted samples in a final volume of 20 µl using SYBR Green 
MasterMix (Life Technology) on a StepOne Real Time PCR system (Life 
Technology, Applied Biosystem). 
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To provide precise quantification of initial target in each PCR reaction, the 
amplification plot is examined and the point of early log phase of product 
accumulation is defined by assigning a fluorescence threshold above background 
defined as the threshold cycle number or Ct. 
Differences in threshold cycle number were used to quantify the relative amount of 
PCR target contained within each tube. Relative expression of different gene 
transcripts was calculated by the Delta-Delta Ct (DDCt) method and converted to 
relative expression ratio (2-DDCt) for statistical analysis (Pfaffl M.W. 2001; Livak 
K.J, Schmittgen T.D 2001). 
All data were normalized to the endogenous reference genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression. Results on RNA were normalized to 
results obtained on RNA from the control, vehicle treated rats. After PCR, a 
dissociation curve (melting curve) was constructed in the range of 60 ºC to 95 ºC to 
evaluate the specificity of the amplification products. The primers used for PCR 
amplification (Tab. 5) were designed using Primer 3. 
  
Primer FORWARD (5’-3’) REVERSE (5’-3’) 
NOP TCAGTTCATTGTGCTCCTGC GCCATACAAGACCTCCCAGA 
ppN/OFQ  TTTGTGACGTTCTGCTGCTC GCATACAGTCCAGAGAGGGC 
pDYN  CCCTCTAATGTTATGGCGGA AGAGACCGTCAGGGTGAGAA 
pENK  CTACAGGCGCGTTCTTCTCT CAGCTGTCCTTCACATTCCA 
pBDNF  GCGGCAGATAAAAAGACTGC CCTATGAATCGCCAGCCAAT 
GAPDH  AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
  
Table 5. Primer sequences used for reverse-transcription-polymerase chain reaction. 
GAPDH = glyceraldehyde-3-phosphate dehydrogenase; pKOP = kappa opioid receptor; pNOP = 
nociceptin opioid receptor; pDYN = prodynorphin; ppN/OFQ = prepronociceptin; pENK = 
proenkephalin; pBDNF = proBDNF 
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3.6 Epigenetic studies 
  
Analysis of histones modification by Chromatin Immunoprecipitation (ChIP) 
and Real Time PCR 
  
Chromatin was prepared from frozen tissues as previously described with 
minor modifications (Dahl J.A., CollasP. 2007): proteins were cross-linked to DNA 
by addition of formaldehyde at a final concentration of 1% in phosphate buffer saline 
(PBS) containing a broad-range protease inhibitor cocktail (PIC) (Roche) and 
butyrate (Sigma), for 8 min at room temperature. The cross-linking reaction was 
quenched by adding glycine to a final concentration of 0.125 M and incubating for 5 
min at room temperature, the sample washed, and lysed thorough resuspension by 
pipetting in 120 ul of lysis buffer. 
The sample was incubated on ice and sonicated for 30 s to shear the DNA to 
fragments ranging in size from 150 to 700 bp, as analyzed by agarose gel 
electrophoresis. 
The lysate was centrifuged at 12 000 g for 10 min at 4°C and the supernatant 
transferred into a chilled tube, leaving around 30 ul of buffer with the pellet. Another 
30 ul of lysis buffer was added and the tube vortexed. After centrifugation as before, 
50 ul of the supernatant was pooled with the first supernatant and sonicated for 
another 2 X 30 s on ice. 
After removing a few µl to serve as "input" DNA, for each immunoprecipitation, 8 
µg of chromatin was diluted 10-fold in RIPA buffer (10 mM Tris-HCl, pH 7.5, 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, 140 
mM NaCl) containing PIC and incubated overnight by rotation with either no 
antibody as control or with 1 - 4 µg of antibody, previously coated with Protein A 
beads (Invitrogen), for 2 hours at 4°C with agitation, against either H3K4me3 
(Abcam, ab8580), H3K27me3 (Millipore, 17-622), H3K9Ac (Millipore, 17-658). 
The beads and associated immune complexes were washed three times with RIPA 
buffer and once with Tris-EDTA buffer. The immune complexes were eluted with 
elution buffer (20 mM Tris-HCl, 5 mM EDTA, 50 mM NaCl) containing proteinase 
K (50 µg/ml) at 68°C for 2 hours, and DNA was recovered by phenol extraction, 
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ethanol precipitated, and resuspended in 50 µl of sterile water. This procedure has 
been described in more detail (Dahl J.A., Collas P. 2007). Thereafter, real-time 
qPCR (RT-qPCR) quantification of the genomic sequences from regions in the rat 
PDYN and PNOC proximal promoter associated with the immunoprecipitated 
proteins were carried out. The primers used for PCR amplification were designed 
using Primer 3 software (Tab. 6) (Rozen S., Skaletsky H. 2000): 
  
Primer  FORWARD (5’-3’)  REVERSE (5’-3’)  
PrompDYN GGCTTCCTTGTGCTTCAG TAGCTGCTCCTGGTGATG 
PrompBDNF TTCGATTCACGCAGTTGTTC CTGAGCCAGTTACGTGACCA 
 
Table 6   Primer sequences used for Real Time PCR. 
  
The relative abundance was assessed by RT-qPCR using  SYBR Green MasterMix 
(Life Technology) on a StepOne Real Time PCR system (Life Technology, Applied 
Biosystem). 
To provide precise quantification of the initial target in each PCR reaction, the 
amplification plot was examined and the point of early log phase of product 
accumulation defined by assigning a fluorescence threshold above background, 
defined as the threshold cycle number or Ct. 
Differences in threshold cycle number were used to quantify the relative amount of 
the PCR targets contained within each tube. After PCR, a dissociation curve (melting 
curve) was constructed in the range of 60 ºC to 95 ºC (22) to evaluate the specificity 
of the amplification products. The relative expression of different transcripts was 
calculated by the delta-delta Ct (DDCt) method and converted to relative expression 
ratio (2-DDCt) for statistical analysis (Livak K.J., Schmittgen T.D. 2001). 
All ChIP data were normalized to the input DNA amounts (Ct values of 
immunoprecipitated samples were normalised to Ct values obtained from 'input'). In 
addition, results on DNA from treated samples were normalized to results obtained 
on DNA from the control sample. Each ChIP experiment was repeated at least three 
times. 
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3.7  N/OFQ levels determination  
 
3.7.1   Extraction  
 
Tissue samples (brain areas) were sonicated in 10 volumes (vol/wt) of boiling 1 M 
acetic acid, and maintained at 90°C for 10 minutes. After centrifugation (12,000 rpm 
for 20 min at 4°C), the supernatants were separated and subjected to 
chromatographic extraction as previously described (Aparicio L.C. et al. 2004). 
Supernatants were mixed with an equal volume of TFA (1% v:v) and loaded onto 
previously equilibrated C 18 cartridges (SEPCOL- 1; Bachem, U.K.). Microcolumns 
were washed twice with 3 ml of 1% TFA and then eluted with 3 ml of 60% 
acetonitrile in 1% TFA. Eluates were lyophilized and stored at -80°C until RIA. 
 
3.7.2   Radioimmunoassay 
 
Immunoreactive N/OFQ (ir-N/OFQ) present in tissue extracts was measured by a 
specific RIA according to a validated procedure (Ploj K. et al. 2000). Lyophilized 
extracts were reconstituted with 50 ml of methanol/0.1% HCl (1/1) and assayed in 
duplicate. Aliquots of 25 µl were mixed with 100 µl of 125I-N/OFQ (Bachem, St. 
Helens, Merseyside, UK) and 100 µl of antiserum (96:2+; kindly supplied by Prof. 
SC I. Nylander, Uppsala University, Sweden). The antiserum was used at the 
appropriate dilution to give 30%-34% binding of the [125I]- N/OFQ (4600e5000 
cpm. The labeled peptide and the antiserum were diluted in a gelatin buffer 
containing 0.15 M NaCl, 0.02% sodium azide, 0.1% gelatin, 0.1% Triton X-100, and 
0.1% BSA in a 0.05 M sodium phosphate buffer (pH 7.4). RIA tubes were incubated 
at 4°C for 24 hours. A charcoal slurry (1 ml/tube) was used to separate free and 
antibody-bound peptide (15% horse serum, 3% charcoal, 0.3% dextran in RIA 
buffer). Bound peptide was separated by centrifugation (5,000 3 g at 4°C), and 1 ml 
aliquots of the supernatants were counted for 1 minute on a Beckman 5,500 gamma 
counter (Beckman, Fullerton, CA). The detection limit of the RIA assay was 1–2 
fmol/tube. RIA curves and data were analyzed using the GraphPad Prism 4 software 
for Windows (GraphPad Software, San Diego, CA). 
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3.8   Primary Cultures   
 
Primary brain cultures derived basically as described by Scherrer et al, 2006.  
Briefly, Newborn NOP-EGFP  mice pups (P0) were decapitated, and appropriate 
brain regions, removed.  Tissue was digested by papain (15 Units/ml; Worthington). 
Cells were plated on poly-D-lysine coated coverslips at a density of 80,000 cells per 
cm2. Cells were grown in neurobasal A medium (Invitrogen) with B27 supplement, 
0.5 mM glutamine, 5 ng/ml basic fibroblast growth factor (bFGF, Sigma), and 
antibiotics.  Internalization studies were conducted 10-14 days after plating. 
 
3.8.1   Time-Lapse Fluorescence Microscopy 
 
Primary cells from NOP-EGFP mice were seeded in glass-bottom, 32-mm 
diameter plastic dishes coated with poly-D-lysine (Sigma). Fully matured primary 
neurons (10–14 days in vitro) were used, and receptor internalization studies were 
performed in the presence of N/OFQ. Samples were observed under a Delta Visione 
Elite Microscope with objective 60X at 37°C. Images were automatically recorded 
during 20 min, with increasing time intervals to avoid bleaching effects because of 
repetitive scanning. Specifically, 20 frames every 10 s followed by 10 frames every 
30 s, and then 12 frames every minute were recorded, for a total of42 images. 
 
 
3.9   Brain Slices.   
 
6-8 week old NOP-EGFP mice were anaesthetized with isofluorane and 
transcardially perfused with  PBS 1X followed by 4% paraformaldehyde.  Brains 
were dissected, washed with a gradient of sucrose 10% 20% and 30%, plunged in 
Optimal Cutting Temperature  (OCT) and stored at -80°C until sectioning.  All brains 
were sectioned coronally on a Leica CM1850 cryostat at the thickness of 16 µm, then 
mounted on polylysine-coated microscope slides, stained with DAPI (Southern 
Biotech). 
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All samples were observed under Delta Vision Elite Microscope and the SoftWorx 
software was used for image acquisition.  
 
 
3.10   Statistical Analysis 
 
Hyperalgesia signs data were analyzed by Dunnett’s test or the two tailed Student’s t-
test. Allodynic signs data from Acetone Test were analyzed non-parametrical 
analysis (Mann–Whitney U-test).  Allodynic signs data from Cold Plate Test were 
statistically asnalyzed using the one-way ANOVA followed by Newmann-Keuls. 
Gene expression data were statistically asnalyzed using the Dunnett’s test or the two 
tailed Student’s t-test. 
Histone modification changes in SC and N/OFQ peptide levels alterations in 
different brain areas were statistically analyzed using the two-tailed Student’s t- test. 
Statistical significance was set at P < 0.05.  
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4.  RESULTS 
 
4.1 Opioid System and BDNF alterations studies in ICR/CD1 
neuropathic mice 
 
4.1.1 Determination of the behavioral signs of neuropathic pain 
 
After recording the baseline values for both CCI and sham groups, the development 
of thermal hyperalgesia and cold allodynia were assessed three, seven and fourteen 
days after surgery using respectively the Hargreaves’s Plantar test and the Acetone 
Test. Sciatic nerve ligation caused a significant decrease of the paw withdrawal 
latency three days after surgery in the CCI animals compared to Sham group (4.111 
± 0.601 vs Sham 9.197 ± 1.931, unpaired t test *P < 0.05, ***P <0.001), and the 
thermal threshold of the CCI group remained lower at 7 and 14 days after sciatic 
nerve ligations compared to Sham animals (respectively, 2.910  ± 0.615 vs Sham 
10.217 ± 1.316, 2.315  ± 0.381 vs Sham 10.507 ± 0.869, unpaired t test, ***P 
<0.001). (Fig. 30a). As shown in Fig. 30b, CCI animals exhibited no allodynic 
response to a cold stimulus (acetone) prior to ligation of the sciatic nerve; three days 
after surgery, there was an increase in the average response to acetone evaporation of 
the CCI animals compared to Sham group (0.708 ± 0.042 vs Sham 0.056 ± 0.035, 
unpaired t test, ***P <0.001). Seven days after ligation there was an enhanced 
increment in the average response of the CCI mice compared to Sham ones (2.340 ± 
0.280 vs Sham 0.389 ± 0.176, unpaired t test, ***P <0.001), with comparable values 
fourtheen days after the lesion (2.233 ± 0.280 vs Sham 0.067 ± 0.041 unpaired t test, 
***P <0.001 ). 
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 a)                  b) 
 
 
     
 
 
 
Figure 30 Determination of behavioural signs of thermal hyperalgesia a) and cold allodynia 
b). 
a) Paw withdrawal latency recorded 0, 3, 7 and 14 days after surgery. All values are expressed as 
means ± standard error (n= 6 per group). Differences among groups were estimated by t-test. *P < 
0.05 vs Sham group. 
b) Allodynic Response Score recorded 0, 3, 7 and 14 days after surgery. All values are expressed as 
means ± standard error ( n= 6 per group). Differences among groups were estimated by Mann-
Whitney U-test. *P < 0.05 vs Sham group. 
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4.1.2 Gene expression studies 
 
In the SC, gene expression studies revealed a significant increase in the mRNA 
levels of pDYN (1.427 ± 0.138 versus sham group equal to 1, dunnet test: *P < 0.05) 
and pBDNF (1.767 ± 0.261 versus sham group equal to 1, dunnet test: *P < 0.05) in 
the group of animals sacrified 7 days after CCI returning to values comparable with 
sham in the group sacrified 14 days after CCI. No significantly differences in the 
mRNA levels of the others genes investigated. (Figure 31a)  
 
 
a)  SC 
 
 
 
 
 
Figure 31a Levels of pNOP, ppN/OFQ, pDYN, pENK and pBDNR  mRNA in the SC of CCI mice, 
sacrified 7 or 14 days after surgery, in comparison with Sham groups, see Materials and Methods 
section for details. Bars represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) method of six 
mice for each group. Expression was normalized to glyceraldehyde-3-phosphate dehydrogenase and 
means of mRNA levels are expressed relative to Sham mice ± standard error of the mean. Differences 
among groups were estimated by t-test. *P < 0.05 versus Sham group. 
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In the DRGs, mRNA levels of ppN/OFQ were increased in both groups of animals 
sacrified 7 days and 14 days after CCI (respectively, 2.22 ± 0.52 versus sham group 
equal to 1, dunnet test: *P < 0.05; 3.59 ± 0.61 versus sham group equal to 1, dunnet 
test: **P < 0.01). Levels of the pNOP mRNA transcript was decrease in the groups 
of animals sacrified 7 days after CCI (0.63 ± 0.06 versus sham group equal to 1, 
dunnet test: **P < 0.01) returning to values comparable with sham in the group 
sacrified 14 days after surgery, whereas no changes were evident in the other genes. 
Levels of pDYN mRNA was not detectable (Figure 31b).  
 
 
b)  DRGs 
 
 
 
 
 
Figure 31b Levels of pNOP, ppN/OFQ, pDYN, pENK and pBDNR  mRNA in the DRGs of CCI 
mice, sacrified 7 or 14 days after surgery, in comparison with Sham groups, see Materials and 
Methods section for details. Bars represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) 
method of six mice for each group. Expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase and means of mRNA levels are expressed relative to Sham mice ± standard error of 
the mean. Differences among groups were estimated by t-test. *P < 0.05 versus Sham group. 
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4.2 Study of BDNF and DYN-KOPr system 
 
4.2.1 Neuropathic BDNF transgenic mice studies 
 
4.2.1.1 Behavioral studies 
 
Behavioral signs of neuropathic pain a) hyperalgesia and b) allodynia were 
assessed by respectively  Hargreaves’s Plantar test and the Cold Acetone or Cold 
Plate Tests  
 
 
a)   Hyperalgesia 
 
A similar development of hyperalgesia was observed in ICR/CD-1 and BDNF 
+/+ mice compared with own Sham control group, with statistically significant 
values at three (respectively, 3.83 ± 0.23 vs sham 9.00 ± 0.37, 3.81 ± 0.42 vs sham 
7.41 ± 0.88, dunnet test **P < 0.01) and seven (respectively, 4.47 ± 0.27 vs sham 
9.00 ± 0.37, 3.91 ± 0.31 vs sham 7.41 ± 0.88, dunnet test **P < 0.01) days after 
surgery. In contrast, a later onset of hyperalgesia was observed in BDNF +/- mice 
compared with Sham animals, with statistically significant values only at seven days 
after surgery (3.53 ± 0.37 vs sham 8.78 ± 1.09, dunnet test **P < 0.01 ) Fig. 32 
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Figure 32  Determination of behavioural signs of thermal hyperalgesia.  
Paw withdrawal latency recorded 3 and 7 days after surgery. All values are expressed as means ± 
standard error ( n= 6 per group). Differences among groups were estimated by dunnet test. **P < 0.01 
versus Sham group. 
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b)   Allodynia 
 
BDNF +/- animals exhibited significantly lower signs of allodynia than 
BDNF+/+ and ICR/CD-1, each group compared with own Sham control mice, at 
seven days after CCI in both the cold acetone (i.e. lower scores Fig. 33a; 
respectively, 1.01 ± 0.35 vs Sham 0.10 ± 0.05, 1.90 ± 0.31 vs Sham 0.25 ± 0.08, 2.03 
± 0.38 vs Sham 0.38 ± 0.17, Mann-Whitney U test *P <0.05 ***P < 0.001 #P < 
0.05) and cold plate the tests (i.e. higher times Fig. 33b; respectively, 13.28 ± 3.05 vs 
Sham 28.8 ± 0.80, 5.65 ± 0.69 vs Sham 29.2 ± 0.49, one-way ANOVA and 
Newman-Keuls ***P < 0.001 ##P < 0.01). 
 
 
 
 
a)               b) 
          
 
 
Figure 33  Determination of behavioural signs of cold allodynia. 
a) Allodynic Response Score recorded 7 days after surgery. All values are expressed as means ± 
standard error (n= 6 per group). Differences among groups were estimated by Mann-Whitney U test. 
*P < 0.05 vs BDNF +/- Sham; ***P < 0.001 vs BDNF +/+ or ICR/CD-1 Sham; #P < 0.05 vs BDNF 
+/+ CCI 7 days. 
b) Paw withdrawal latency recorded 7days after surgery. All values are expressed as means ± standard 
error (n= 6 per group). Differences among groups were estimated by ANOVA and Newman-Keuls. 
***P < 0.001 vs BDNF +/+ or BDNF +/- Sham; ## P < 0.01 vs BDNF +/- CCI 7 days. 
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4.2.1.2   Gene expression 
 
the increase in pDYN gene expression  observed in the SC of ICR CD-1 mice at 
seven days after CCI (see Fig. 31a) was not detected in lesioned BDNF +/-  mice 
compared with Sham animals, at the same interval  Fig. 34. 
 
 
        
              
 
 
Figure 34 Levels of pDYN mRNA in the SC of BDNF +/-  CCI mice, sacrificed 7 days after 
surgery, in comparison with Sham groups, see Materials and Methods section for details. Bars 
represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. 
Expression was normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA 
levels are expressed relative to Sham mice ± standard error of the mean. Differences among groups 
were estimated by t-test.  
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4.2.2 ICR/CD1 neuropathic mice studies 
 
4.2.2.1   Gene expression studies 
 
In the brain areas, gene expression studies revealed a significant increase in the 
mRNA levels of pBDNF in the Amy (1.74 ± 0.15 versus sham group equal to 1, 
unpaired t test: *P < 0.05), the ACCX (1.55 ± 0.10 versus sham group equal to 1, 
unpaired t test: **P < 0.01) and the PFCx (1.40 ± 0.07 versus sham group equal to 1, 
unpaired t test: *P < 0.05) in the CCI animals, whereas mRNA levels were 
significantly decreased in Th (0.51 ± 0.09 versus sham group equal to 1, unpaired t 
test: **P < 0.01). No changes were evident in the other areas. (Fig. 35a)  
 
 
a)  pBDNF 
 
 
 
 
 
Figure 35a Levels of pBDNF mRNA in the brain areas of CCI mice, sacrified 14 days after surgery, 
in comparison with Sham groups, see Materials and Methods section for details. Bars represent 2-
DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. Expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are expressed 
relative to Sham mice ± standard error of the mean. Differences among groups were estimated by t-
test. *P < 0.05 versus Sham group. 
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Levels of the pDYN mRNA transcript were increased in the CCI groups of animals 
in the ACCx (3.98 ± 0.39 versus sham group equal to 1, unpaired t test: ***p < 0.001 
) and PFCx (2.14 ± 0.021 versus sham group equal to 1, unpaired t test: *p < 0.05) 
whereas were decreased in BS (0.71 ± 0.05 versus sham group equal to 1, unpaired t 
test: *p < 0.05). No significant changes were observed in the other brain regions. 
(Fig. 35b) 
 
 
b)  pDYN 
 
 
 
 
 
 
Figure 35b  Levels of pDYN  mRNA in the brain areas of CCI mice, sacrified 14 days after surgery, 
in comparison with Sham groups, see Materials and Methods section for details. Bars represent 2-
DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. Expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are expressed 
relative to Sham mice ± standard error of the mean. Differences among treatments were groups by t-
test. *P < 0.05 versus Sham group. 
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mRNA levels of pKOP were significant decreased in NAc (0.34 ± 0.10 versus sham 
group equal to 1, unpaired t test: ***p < 0.001), Th (0.75 ± 0.08 versus sham group 
equal to 1, unpaired t test: *p < 0.05), ACCx (0.44 ± 0.10 versus sham group equal to 
1, unpaired t test: *p < 0.05) and SSCx (0.50 ± 0.08 versus sham group equal to 1, 
unpaired t test: *p < 0.05) whereas no evident changes occurred in the other cerebral 
areas. (Fig. 35c) 
 
 
c)  pKOP 
 
 
 
 
Figure 35c  Levels of pKOP mRNA in the brain areas of CCI mice, sacrified 14 days after surgery, 
in comparison with Sham groups, see Materials and Methods section for details. Bars represent 2-
DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. Expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are expressed 
relative to Sham mice ± standard error of the mean. Differences among groups were estimated by t-
test. *P < 0.05 versus Sham group. 
 
 
 
 
 
 
 
  
 
113 
 
4.2.2.2 Epigenetic studies: Histone modifications 
 
Adult male ICR/CD1 mice were subjected to a right sciatic nerve lesion to 
investigate whether chronic pain condition could evoke epigenetic changes (histone 
modifications) in the pDYN and pBDNF promoter regions associated with the 
different previously demonstrated genes up-regulation in the SC of animals sacrified 
7 days after surgery. 
We found a significant decrease of H3K27me3 (0,45 ± 0,09 versus Sham = 1, p< 
0,05) and H3K9me2 (0,45 ± 0,09 versus Sham = 1, p< 0,05) in pDYN promoter 
region as well as a significant decrease in H3K4me3 for pDYN promoter (1,7 ± 0,3, 
p < 0,05). No significantly alterations were observed in pBDNF promoter region 
(Fig. 36). 
 
 
 
 
a)           b) 
                                                                          
 
Figure 36 Real Time-qPCR analyses of H3K4me3, H3K9Ac, H3K27me3 and H3K9me2 
immunoprecipitated DNA fragments at a) pDYN and b) pBDNF promoters. ChIP showing the levels 
of specific histone modification normalized to total input DNA in CCI mice (n =6) or Sham mice (n 
=6). Data are expressed as means ± SE of triplicate independent samples.*P < 0.05 vs. Sham; t-test. 
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4.3 Study of N/OFQ-NOPr system 
 
4.3.1 Gene Expression 
 
In cerebral areas, levels of the ppN/OFQ mRNA transcript were segnificantly 
decreased in BS (0.65 ± 0.02 versus sham group equal to 1, unpaired t test: *p < 
0.05), Hippo (0.76 ± 0.05 versus sham group equal to 1, unpaired t test: *p < 0.05), 
Amy (0.71 ± 0.07 versus sham group equal to 1, unpaired t test: *p < 0.05), Nac 
(0.39  ± 0.08 versus sham group equal to 1, unpaired t test: *p < 0.05) and CP (0.38 ± 
0.05 versus sham group equal to 1, unpaired t test: *p < 0.05. No significantly 
changes were observed in others brains areas (Fig 37a). 
 
 
a)   ppN/OFQ  
 
 
 
 
 
 
Figure 37a  Levels of ppN/OFQ mRNA in the brain areas of CCI mice, sacrified 14 days after 
surgery, in comparison with Sham groups, see Materials and Methods section for details. Bars 
represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. 
Expression was normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA 
levels are expressed relative to Sham mice ± standard error of the mean. Differences among groups 
were estimated by t-test. *P < 0.05 versus Sham group. 
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pNOP gene expression was segnificantly decreased in BS (0.54 ± 0.08 versus sham 
group equal to 1, unpaired t test: *p < 0.05), and CP (0.57 ± 0.12 versus sham group 
equal to 1, unpaired t test: *p < 0.05. No significantly changes were observed in 
others brains areas (Fig. 37b). 
 
b)  pNOP 
 
 
 
 
 
 
Figure 37b Levels of pNOP mRNA in the brain areas of CCI mice, sacrified 14 days after surgery, 
in comparison with Sham groups, see Materials and Methods section for details. Bars represent 2-
DDCt value calculated by Delta-Delta Ct (DDCt) method of six mice for each group. Expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are expressed 
relative to Sham mice ± standard error of the mean. Differences among groups were estimated by t-
test. *P < 0.05 versus Sham group. 
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4.3.2 Quantification of active peptide levels 
 
In Amy, levels of ir-N/OFQ were significantly higher in CCI group compared with 
Sham animals (15153.74 ± 2215.96 versus 7504.56 ± 284.85, unpaired t test: *p < 
0.05) whereas no significant alteration were observed in other brain regions (Fig. 38). 
 
 
 
 
 
 
 
 
Figure 38  N/OFQ levels in brain areas  of CCI mice, sacrified 14 days after surgery, in 
comparison with Sham groups, see Materials and Methods section for details. All values are 
expressed as means ± standard error (n= 5 per group). Differences among groups were 
estimated by t-test. *P < 0.05 versus Sham group. 
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4.3.3 NOP-EGFP mice: charaterization and validation of knock-in mouse strain 
 
Knock-in mice were constructed so that the NOP receptor with eGFP fused at 
the C-terminus is expressed in place of the native receptor with eGFP attached to the 
C-terminal of NOP receptors.  
 
4.3.3.1 Primary Cultures: Internalization studies 
 
Internalization studies conducted on hippocampal or cortical primary neurons 
showed that 1.0 µM N/OFQ addition causes internalization of receptors. 
Fig. 39 (top view of the neuron cell) shows that fluorescent signal from NOP-eGFP 
gradually disappear at 0, 5 min and 15 min after drug addition, from the cell 
membrane to the inside of the cell. 
 
 
0 min.             5 min.                                 15 min. 
 
 
 
Figure 39 Real-time Fluorecense  Imaging of N/OFQ (µM )-induced NOP-eEGFP redistribution in 
primary cortical  neurons. A representative experiment is shown (n= 4  referring to cell cultures from 
pools of 4 to 6 mouse pups). Images at 0, 5 and 15 min of treatment (Magnificence 60x). 
 
 
Similarly, cells showed in Fig. 40 and Fig. 41 (observation of the equatorial plane of 
the neuron cells) displayed a rearrangement of the NOP-eGFP signal, from diffused 
around cell body and processes to dots organized , from 0 to 20 minutes after drug 
addition. 
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0 min.              20 min. 
 
     
 
Figure 40 Real-time Fluorecense Imaging of N/OFQ (1µM)-induced NOP-eEGFP redistribution in 
primary hippocampal neurons. A representative experiment is shown (n= 4  referring to cell cultures 
from pools of 4 to 6 mouse pups). Images at 0 and 20 min of treatment (Magnificence 60x). 
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0 min.              20 min. 
 
     
 
Figure 41  Real-time Fluorecense Imaging of N/OFQ (1µM)-induced NOP-eEGFP redistribution in 
primary hippocampal neurons. A representative experiment is shown (n= 4  referring to cell cultures 
from pools of 4 to 6 mouse pups). Images at 0 and 20 min of treatment (Magnificence 60x). 
 
Cell Neuron in Fig. 42 shows a high signal from NOP-EGFP already internalized at 
time 0 before drug addition.  
 
 
                               
 
 
Figure 42 Real-time Fluorecense Imaging of primary cortical neurons. 
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4.3.3.2 Brain Sections: Localization studies 
 
Analysis of brain slices showed that the receptors appear to be located in brain 
regions, such as a) cingulate cortex (Cg) and b) hippocampus (Hippo), previously 
demonstrated to contain NOP receptor mRNA and NOP receptor binding sites. 
 
a)   Cg, in Fig. 43a is shown Cg2 (left top) to the edge with the white matter (right 
bottom). Fluorescent signal was present in in neuron of the Cg2 but not cell of the 
white matter. In Fig 43b is shown Cg1 region. Fluorescent signal was present around 
neurons and in connected cell processes.  
 
 
a)                                                                 b) 
     
 
 
Figure 43  Anatomical distribution of fluorescence in NOP-eGFP mice.  
a) Fluorecense Images of Cg2 at the edge with white matter. 
b) Fluorencense Imges of Cg1 region. 
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b)   Hippo, in Fig 44a, b, c is shown NOP-eGFP signal around neuron cell body and 
connected cell processes, in different hippocampus areas. 
 
 
a)                                         b)                                        c) 
 
 
 
Figure 44  Anatomical distribution of fluorescence in NOP-eGFP mice. Fluorecense Images of 
Hippo. 
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5. DISCUSSION 
 
Neuropathic pain has been described as the “most terrible of all tortures 
which a nerve wound may inflict” and arises as a consequence of nerve injury either 
of the peripheral or central nervous system. Following peripheral nerve injury, a 
cascade of events in the primary afferents leads to peripheral sensitization resulting 
in sensory abnormalities including stimulus-independent persistent pain or abnormal 
sensory perception such as hyperalgesia and allodynia   (Woolf C.J., Mannion R.J. 
1999). 
The precise mechanisms underlying neuropathic pain and the relationship among 
different mechanisms are not fully understood. Peripheral nerve injury is followed by 
a change in expression of neurotransmitters, neuromodulators, growth factors and 
neuroactive molecules in primary afferent neurons located in dorsal root ganglion of 
the spinal cord. These changes in-turn induce sensitization of primary afferents 
inputs (peripheral sensitization) leading to exaggerated pain perception in an injured 
tissue or territory innervated by an injured nerve. Apart from the pain 
hypersensitivity in an injured tissue, neuropathic pain also spreads to the adjacent 
non-injured extra-territory regions (extraterritorial pain) and contralateral parts 
(mirror image pain) (Woolf C.J., Mannion R.J. 1999) indicating the esistence of 
maladaptive changes in neural network in the central nervous system (central 
sensitization). The induction of central sensitization has been identified at the spinal 
cord level (dorsal horn neurons, second order neurons) and in the brain regions (third 
order neurons). A number of reports have suggested the neuroplastic changes in 
different brain areas that are responsible for central sensitization and behavioral 
alterations in peripheral nerve injury-induced neuropathic pain (Jaggi A.S., Singh N. 
2011).  
Development of animal models has contributed immensely in understanding the 
chronic pain and underlying peripheral as well as central pathogenic mechanisms. 
The ideal animal models should result in reproducible sensory deficits such as 
allodynia, hyperalgesia and over a sustained period. In the present study we used 
chronic constriction injury to the sciatic nerve (CCI), which more closely resembles 
behavior (hyperalgesia and allodynia) of peripheral neuropathy in rodents (Colleoni 
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M., Sacerdote P. 2010). The first result of the present study is that the experimental 
conditions used were able to evoke neuropathic signs of hyperalgesia and allodynia 
for a prolonged period (i.e. 14 days). Therefore our results proved that we were in the 
right experimental conditions. 
Although the presence of many evidences as described above (Jaggi A.S., Singh N. 
2011), it is generally difficult to clearly understand whether changes in RNA levels 
reflect a possible involvement of a specific gene in chronic pain neuroplasticity. The 
main goal of our study was to try to correlate the effects of peripheral nerve injury on 
opioids and BDNF gene expressions. 
 
BDNF and DYN-KOPr system 
 
Many studies examined dynorphinergic system and BDNF activity during 
neuropathic pain conditions (Mika J. et al. 2011; Vanelderen P. et al. 2010). 
Although dynorphin is commonly characterized as an endogenous opioid peptide, 
considerable evidence reveals that dynorphin is actually pronociceptive in chronic 
pain states (Wang Z. et al. 2001).  Several lines of evidence proposed a central role 
for BDNF in the initiation of central sensitization caused by an alteration of the Cl- 
cell gradient followed by the inversion of GABAergic inhibitory activity (Kohno T. 
et al. 2005) and by an increase in the NMDA receptors-mediated excitatory activity 
suggesting a pro-nociceptive effect of this neutrophin (Vanelderen P. et al. 2010). 
Here we observed a transient up-regulation of both pDYN and pBDNF mRNA levels 
in the SC of injured animals at seven days after surgery returning to values 
comparable with control animals at fourteen days. pDYN gene expression data 
appear to be consistent with the hypothesis that elevated spinal dynorphin is required 
for maintaining neuropathic pain suggesting that endogenous dynorphin is a key 
mediator of some aspects of neuropathic pain states (Lai J. et al. 2001). pBDNF data 
seem to be related to the possibility previously proposed that BDNF functions as a 
final common path for a convergence of perturbations that culminate in the 
generation of neuropathic pain. Peripheral nerve injury activates spinal microglia. 
Although a variety of neuropeptides, cytokines, chemokines and neurotransmitters 
have been implicated at various points in this process, much of the information 
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transfer between activated microglia and neurons, at least in this context, may be 
explicated by BDNF  (Biggs J.E. et al. 2010). Moreover, the simultaneous up-
regulation of pDYN and pBDNF seems sustain the hypothesis recently proposed that 
dynorphin could act as a downstream effector of some BDNF actions (Logrip M.L. et 
al. 2008).  
These data indicate that some modifications of the biosynthesis of neurotransmitters 
highly involved in this pathology occur early after the injury and cannot be more 
evident at later intervals. 
In parallel, behavioural and neurochemical data obtained in BDNF transgenic mice 
seem confirmed the hypothesis proposed above. A similar development of 
hyperalgesia (plantar test) was observed in ICR/CD-1 and BDNF +/+ (wild type) 
mice. In contrast, a later onset of hyperalgesia was observed in BDNF +/- mice 
(BDNF lacking mice). In addition, BDNF +/- animals exhibited significantly lower 
signs of allodynia than BDNF +/+, in both the cold plate (i.e. higher times) and the 
acetone tests (i.e. lower scores). These behavioral results support a role for BDNF in 
mechanisms underlying the development of allodynia and hyperalgesia, thus 
confirming its involvement in neuroplasticity leading to neuropathic pain conditions. 
Furthermore, the increase in pDYN gene expression observed in the spinal cord of 
ICR/CD-1 mice at seven days after CCI was not detected in lesioned BDNF +/-  
mice, at the same interval. This result suggest some relationship between BDNF and 
DYN and seems to confirm the existence of a possible BDNF and DYN cross-talk. 
Since epigenetic mechanisms seem to play a role in neurol plasticity resulting from 
chronic pain (Chwang W.B. et al. 2007; Koshibu K. et al. 2009; Lubin F.D. et al. 
2008), we here also studied the involvement of epigenetic mechanisms in the pDYN 
and pBDNF genes expression changes observed seven days after surgery in the SC. 
We observed a close relationship between selective chromatin modifications and 
pDYN genes expression. In particolar, our study revealed a decrease of H3K27me3 
and H3K9me2, repressive marks, in the pDYN gene promoter region. These data are 
in agreement with the gene expression increase previously observed in the same 
interval after the nerve injury. However, concerning activating marks, we observed a 
decrease of H3K4me3 in the pDYN gene promoter region and no changes of 
H3K9ac. Moreover, no changes of histone modifications were observed in the 
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pBDNF gene promoter region. These last evidences seem to be not directly 
associated with gene expression changes. This could be possibly explained by 
different hypothesis. First of all, it has to be taken under consideration the 
complexity of gene regulation by histone modifications (Barski A. et al. 2007) and 
that multiple modifications may function cooperatively to prepare chromatin for 
transcriptional activation.  
One possibility for both pDYN and pBDNF gene could be found in the already 
mentioned and underlined transient nature of their mRNA increase. Could be 
possible that at the time of investigation activating phenomena are in a shutdown 
process, while repressive phenomena are still inactive. Moreover, the already 
mentioned role of downstream effector of DYN in BDNF acting, could explain why 
epigenetic mechanisms are still operating in pDYN gene promoter region, while no 
changes of histone modifications are present in pBNDF gene promoter region. 
The peripheral nerve injury has been also reported to induce neuroplastic changes in 
different brain regions (Jaggi A.S., Singh N. 2011). Here we also investigated gene 
expression alterations in different brain regions, fourteen days after surgery when the 
painful condition is fully established. Results indicated that evident alterations of the 
investigated systems occur. In particular, pDYN gene expression was found to be up-
regulated in the ACCx and PFCx of the CCI mice, while his mRNA levels were 
found to be significantly lower than in control animals in the BS. At the same 
interval, pKOP receptor biosynthesis was found to be down-regulated in the NAc, 
the Th, the ACCx an SSCx. These data seem to further confirm the involvement of 
DYN-KOPr system in neuroplasticity occurring in neuropathic pain. Alterations in 
the ACCx appear particularly interesting. The higher pDYN up-regulation and the 
simultaneous down-regulation of the pKOP receptor suggest that a pronounced 
increase in the ligand availability lead to a down-regulation of his receptor. 
The decrease of pDYN level in the BS could be related with the alterations of 
functionality of the descending control systems of nociception for which important 
and fine regulation mechanisms exist at this neuraxis level. 
Concerning BDNF alterations, particulary interesting is the simultaneously up-
regulation of both pBDNF and pDYN mRNA levels in the same brain areas (ACCx 
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and PFCx). These data could further confirm the close relationship between the these 
two neuropeptidergic systems. 
Experiencing stressful life events, such as chronic pain, increase the risk of later 
developing anxiety and depressive disorders. While it is well established that Amy, 
PFCx and Hippo are key brain structures in fear memory processing (McGaugh J.L. 
2004; Herry C. et al. 2008; Likhtik E. et al. 2008), it is not well known which 
neurotransmitters or neuromodulators are involved. In the present study we observed 
increased pDYN mRNA in the PFCx of injured mice that seems to be consistent with 
a recently proposed role for the dynorphin in the extinction of negative fear 
memories related to stressful situations (Bilkei-Gorzo A. et al. 2012), such as 
neuropathic pain. Once again, we also observed pBDNF up-regulation in the Amy of 
CCI animals in agreement with a recent study proposing BDNF as a mediator of 
susceptibility of fear conditioning in the Amy. 
 
N/OFQ-NOPr system 
 
Nociceptine system is widely recognized to be involved in chronic pain (Mika J. et 
al. 2011). Despite the many advances in our understanding of the involvement of 
different neuropeptide systems in pain, the precise function of this system has not yet 
been fully characterized. It has been clearly documented that the induction of chronic 
pain states, especially neuropathy, is associated with an up-regulation of N/OFQ, as 
indicated by enhanced expression of p/NOFQ protein and/or mRNA (Mika J. et al. 
2010). Moreover, it has been shown that neuropathic and other chronic pain states 
are associated with elevations of DRG content for N/OFQ (Mika J. et al. 2010). 
Consistent with these evidences, here we observed an up-regulation of ppN/OFQ in 
the DRGs of injured mice seven days after surgery, with further increased values at 
fourteen days. In contrast, we also found a down-regulation of pNOP in DRGs of 
CCI mice seven days after surjery, returning to values comparable with sham at 
fourteen days. This result could be explained as an enhanced increase in the ligand 
availability lead to a down-regulation of his receptor. 
As already mentioned, a damage to a peripheral nerve is able to induce neuroplastic 
changes in different brain regions (Jaggi A.S., Singh N. 2011). For this reason we 
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also investigated gene expression alterations in different brain regions, fourteen days 
after surjery that is at the time when we observed a pronounced ppN/OFQ mRNA 
up-regulation in the DRGs. 
The decreased of both ppN/OFQ and pNOP mRNAs levels observed in the BS could 
be related to nociception. Indeed, although this area is involved in the modulation of 
wide range of brain functions, the modulation of descending control system of 
nociception is one of the most important in this context. In this area, nociceptive 
transmission is directly controlled by the gigantocellular paragigantocellular nuclei 
as well as by the raphe magnus nucleus.  
Concerning the other brain regions investigated, gene expression changes seem to be 
more relevant in brain areas associated with the modulation of the affective-
emotional component of pain than with areas related to the modulation of 
nociceptive transmission. In particular, we observed down-regulation of ppN/OFQ 
mRNA levels in the Hippo, Amy, NAc and CP. Furthermore, we also observed a 
decrease of pNOP gene expression in the CP.  
As already mentioned neuropathic pain cause neuroplastic changes in several brain 
areas including the amygdala and the striatum (Jaggi A.S., Singh N. 2011). Indeed, 
neuroplastic changes in the amygdala have been suggested to be responsible for the 
development of depressive-like behavior in subjects affected by prolonged painful 
conditions (Gonçalves L. et al. 2008). Moreover, morpho-functional alterations have 
recently been described in the Hippo, together with anxiety behavior changes, in a 
mouse model of neuropathic pain (Mutzo A.A. et al. 2012). ppN/OFQ gene 
expression alterations observed in these areas seem to be consistent with the already 
known involvement of this system in the anxiety/depressive states, proved by the 
anxiolytic and antidepressant effects respectively exerted by NOP agonists and 
antagonists (Calò G. et al. 2000) as well as by the reduced anxiety-like behavior in 
restraint rats after N/OFQ microinjection into the central nucleus of Amy 
(Ciccocioppo R. et al. 2014). 
In addition, concerning changes observed in the NAc and CP, it is interesting to note 
that these areas include neuronal pathways modulate through dopamine important 
central functions such as reward/aversion (in particular in the NA), but also 
descending control system of nociception (CP) (Jaggi A.S., Singh N. 2011). The 
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involvement of the N/OFQ-NOPr system in the mechanisms of reward/aversion (Xu 
X. et al. 2000), together with the evidence that N/OFQ is able to attenuate both the 
basal and the cocaine-induced increase in extracellular DA in the NAc (Lutfy K. et al. 
2001) and the certainly aversive condition represented by neuropathic pain could 
explain, at least in part, the involvement of this system in NAc. On the other hand, 
changes observed in the CP could be explained with the well-known involvement of 
the investigated system in the control of nociception. In this context, alteration in the 
levels of the inhibitory neuro-mediator N/OFQ could easily affect the release of 
mediators such as GABA or excitatory amino acids that play a crucial role in the 
functionality of the descending system. 
In addition, here we also studied alterations of bioactive N/OFQ levels in the same 
brain regions, in the same experimental conditions. We were able to observe elevated 
N/OFQ levels in the Amy of injured mice compared to Sham animals, whereas no 
significant peptide levels changes were observed in the other investigated brain 
areas. This result seems to be related with the proposed involvement of both Amy 
and Nociceptin system in the development of depressive-like behavior in subjects 
with chronic pain. On the other hand, the elevated bioactive N/OFQ levels seem to 
be in contrast with the its simultaneously gene expression down-regulation. This 
inconsistency could be explained in term of negative feed-back since pronounced 
increase in the bioactive peptide availability lead to a down-regulation of its 
precursor. 
 
NOP-EGFP mice 
 
Internalization of NOP receptors has been studied in transfected cells, using various 
fusion proteins, including C-terminal fused GFP. In transfected cells NOP receptor 
agonists induce internalization (Spampinato S. et al. 2002). Moreover, NOP 
receptors apparently can heterodimerize with all of the opiate receptors.  NOP 
receptor activation was found to induce internalization of µ, δ, and κ receptors when 
co-transfected into HEK cells (Evans R.M. et al. 2010). The formation of 
opioid/NOP receptor heterodimers could have profound effect on nociceptive 
processing. However, studying these phenomena in a native system has been 
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impossible. Kieffer and colleagues produced the first transgenic mice containing the 
delta opioid receptor with enhanced Green Fluorescent Protein attached on the C-
terminal (Scherrer G. et al. 2006). The visualization of receptors has long been a 
central part of the understanding of a receptor system.  Visualization can provide 
information as to the location and trafficking of these important membrane proteins, 
leading to a better understanding of the activation and inactivation of the receptors. 
Here we focused our attention on the characterization and validation of the NOP-
EGFP mice strain. This study in currently in progress and here we presented 
preliminary data. We observed that N/OFQ somministration was able to induce NOP 
receptor internalization in primary neurons. However, we also found NOP receptor 
already internalized in different cells before drug addition, suggesting that in basal 
conditions receptor could be organized in storage vesicles. Analysis on brain slices 
showed that the receptors appear to be located in brain regions, previously 
demonstrated to contain NOP receptor mRNA and NOP receptor binding sites (Neal 
Jr C.R. et al 1999). In particular, we observed that EGFP signal was specific in the 
Cingulate cortex and in the Hippocampus. Moreover, specific fluorescent signal was 
present around neuron cells and in cell connecting processes. 
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6. CONCLUSIONS AND PERSPECTIVES 
 
Chronic pain is one of the most prevalent health problems in our modern world. 
Affecting approximately one in five adults, chronic pain is associated with a 
significantly reduced quality of life and a higher risk of depression and other mental 
health disorders (Breivik H. et al. 2006; Gureje O. 1998). 
It has not been easy to develop novel and effective classes of analgesic drugs - there 
have been almost no new registrations in the past 15 years. There has been much 
discussion about the reasons for past failures and this has stimulated an interest in 
exploring novel mechanisms. There are three main biological mechanisms that 
contribute to persistent pain: peripheral sensitization of primary nociceptors within 
the dorsal root ganglion; central sensitization of spinal interneurons; and descending 
modulation of the pain signal from the brainstem and higher cortical centers. At all 
levels of processing, significant cellular and molecular changes occur, such as large 
alterations in the transcriptional profile of these tissues (Crow M. et al. 2013). 
The data on BDNF and DYN-KOPr system confirm a role of these system in 
neuronal plasticity resulting from chronic pain (Biggs J.E. et al. 2010; Lai J. et al. 
2001) and the hypothesis of  a close relationship between the these two 
neuropeptidergic systems (Logrip M.L. et al. 2008).  
The linkage between gene expression alterations and epigenetic modulation in pDYN 
and pBDNF promoters following nerve injury confirm the possible involvement of 
chromatin remodeling mechanism in chronic pain neuroplasticity (Denk F., 
McMahon S.B. 2012). 
The data on N/OFQ-NOPr system confirm the involvemente of this system in the 
neuroplastic alterations underlying the development and maintenance of 
chronic/neuropathic pain and also suggest its involvement in the regulation of mood 
disorders accompanying the chronic painful state. 
The characterization of the NOP-EGFP mice confirm the usefulness of this 
innovative transgenic mouse strain for the receptor visualization in native tissue, 
therefore internalization and other trafficking can be seen in real time. 
Overall, our results could be important to partially fill the lack of knowledge of 
which and how neuropeptidergic systems are involved in neuroplastic mechanism 
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occurring in neuropathic pain that lead to establish the chronic condition and suggest 
the possibility of using drugs acting on these systems for the treatment of this 
invalidating desease. 
 
A deepened knowledge of the neuroanatomy, neurophysiology, neurochemistry and 
neuroplasticity of chronic/neuropathic pain is needed to identify new targets allowing 
the development of innovative therapeutic strategies for the prevention of 
neuropathic pain establishment. 
 
 
 
 
 
 
 
. 
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